THERESA DOYLE

H.R. 1781 - Payment Commission Data Act of 2019: Issues regarding providing the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to drug pricing and rebate data. H.R. 938 - Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019: Issues regarding discouraging parking of 180-day exclusivity by a first generic applicant that is blocking the approval of other generics. H.R. 1520 - Purple Book Continuity Act of 2019: Issues regarding codifying publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book; Publication and regular updating of the Purple Book electronically on the FDAs website. H.R. 1503 - Orange Book Transparency Act of 2019: Issues regarding ensuring that the Orange Book is accurate and up-to-date, by requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019: Issues regarding brand-name and generic drug manufacturers entering into agreements in which the brand-name drug manufacturer pays the generic manufacturer to keep a generic equivalent off the market. H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 1385 - State Allowance for a Variety of Exchanges (SAVE) Act: Issues regarding federal funds to establish state-based Marketplaces. H.R. 1386 - Expand Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act: Issues regarding funding for Federally-Facilitated Marketplace navigator program; requirements for navigator entities in each state; Health and Human Services ensuring that navigator grants are awarded to entities with demonstrated capacity to carry out the duties specified in the Affordable Care Act. H.R. 987 - Marketing and Outreach Restoration to Empower (MORE) Health Education Act of 2019: Issues related to restoring outreach and enrollment funding to assist consumers in signing up for health care. H.R. 1010 - Issues regarding Short-Term, Limited Duration Insurance. H.R. 986 - Protecting Americans with Preexisting Conditions Act of 2019: Issues regarding rescinding Section 1332 guidance of the ACA promulgated in October 2018. H.R. 1425 - State Health Care Premium Reduction Act: Issues regarding state reinsurance program and providing financial assistance to reduce out-of-pocket costs. H.R. 820 - Public Health Service Act: Issues regarding National Institutes of Health support to collect the medical specimens and information of children with selected cancers that have the least effective treatments. H.R. 2069 - The SPIKE Act, H.R. 2113 - STAR Act, H.R. 2115 - Public Disclosure of Drug Discounts Act, H.R. 2296 - FAIR Drug Pricing Act, H.R. 2376 - Prescription Pricing for the People Act, H.R, 2757 - Creating Lower Cost Alternatives for Your Prescription Drugs Act, S. 657 - Drug Price Transparency (DPT) Act: Issues relating to drug and price transparency. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Regarding all provisions. S. 80, S. 172 - Issues regarding repeal and delay of the health insurer fee. Issues pertaining to surprise billing, including benchmark payments and arbitration models.

H.R. 1781 - Payment Commission Data Act of 2019: Issues regarding providing the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to drug pricing and rebate data. H.R. 938 - Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019: Issues regarding discouraging parking of 180-day exclusivity by a first generic applicant that is blocking the approval of other generics. H.R. 1520 - Purple Book Continuity Act of 2019: Issues regarding codifying publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book; Publication and regular updating of the Purple Book electronically on the FDAs website. H.R. 1503 - Orange Book Transparency Act of 2019: Issues regarding ensuring that the Orange Book is accurate and up-to-date, by requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019: Issues regarding brand-name and generic drug manufacturers entering into agreements in which the brand-name drug manufacturer pays the generic manufacturer to keep a generic equivalent off the market. H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 1385 - State Allowance for a Variety of Exchanges (SAVE) Act: Issues regarding federal funds to establish state-based Marketplaces. H.R. 1386 - Expand Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act: Issues regarding funding for Federally-Facilitated Marketplace navigator program; requirements for navigator entities in each state; Health and Human Services ensuring that navigator grants are awarded to entities with demonstrated capacity to carry out the duties specified in the Affordable Care Act. H.R. 987 - Marketing and Outreach Restoration to Empower (MORE) Health Education Act of 2019: Issues related to restoring outreach and enrollment funding to assist consumers in signing up for health care. H.R. 1010 - Issues regarding Short-Term, Limited Duration Insurance. H.R. 986 - Protecting Americans with Preexisting Conditions Act of 2019: Issues regarding rescinding Section 1332 guidance of the ACA promulgated in October 2018. H.R. 1425 - State Health Care Premium Reduction Act: Issues regarding state reinsurance program and providing financial assistance to reduce out-of-pocket costs. H.R. 820 - Public Health Service Act: Issues regarding National Institutes of Health support to collect the medical specimens and information of children with selected cancers that have the least effective treatments. H.R. 2069 - The SPIKE Act, H.R. 2113 - STAR Act, H.R. 2115 - Public Disclosure of Drug Discounts Act, H.R. 2296 - FAIR Drug Pricing Act, H.R. 2376 - Prescription Pricing for the People Act, H.R, 2757 - Creating Lower Cost Alternatives for Your Prescription Drugs Act, S. 657 - Drug Price Transparency (DPT) Act: Issues relating to drug and price transparency. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Regarding all provisions. S. 80, S. 172 - Issues regarding repeal and delay of the health insurer fee. Issues pertaining to surprise billing, including benchmark payments and arbitration models.

H.R. 1781 - Payment Commission Data Act of 2019: Issues regarding providing the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to drug pricing and rebate data. H.R. 938 - Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019: Issues regarding discouraging parking of 180-day exclusivity by a first generic applicant that is blocking the approval of other generics. H.R. 1520 - Purple Book Continuity Act of 2019: Issues regarding codifying publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book; Publication and regular updating of the Purple Book electronically on the FDAs website. H.R. 1503 - Orange Book Transparency Act of 2019: Issues regarding ensuring that the Orange Book is accurate and up-to-date, by requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019: Issues regarding brand-name and generic drug manufacturers entering into agreements in which the brand-name drug manufacturer pays the generic manufacturer to keep a generic equivalent off the market. H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 1385 - State Allowance for a Variety of Exchanges (SAVE) Act: Issues regarding federal funds to establish state-based Marketplaces. H.R. 1386 - Expand Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act: Issues regarding funding for Federally-Facilitated Marketplace navigator program; requirements for navigator entities in each state; Health and Human Services ensuring that navigator grants are awarded to entities with demonstrated capacity to carry out the duties specified in the Affordable Care Act. H.R. 987 - Marketing and Outreach Restoration to Empower (MORE) Health Education Act of 2019: Issues related to restoring outreach and enrollment funding to assist consumers in signing up for health care. H.R. 1010 - Issues regarding Short-Term, Limited Duration Insurance. H.R. 986 - Protecting Americans with Preexisting Conditions Act of 2019: Issues regarding rescinding Section 1332 guidance of the ACA promulgated in October 2018. H.R. 1425 - State Health Care Premium Reduction Act: Issues regarding state reinsurance program and providing financial assistance to reduce out-of-pocket costs. H.R. 820 - Public Health Service Act: Issues regarding National Institutes of Health support to collect the medical specimens and information of children with selected cancers that have the least effective treatments. 657 - Drug Price Transparency (DPT) Act: Issues relating to drug and price transparency. S. 80, S. 172 - Issues regarding repeal and delay of the health insurer fee. Issues regarding surprise billing, including benchmark payments and arbitration models.

H.R. 1781 - Payment Commission Data Act of 2019: Issues regarding providing the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to drug pricing and rebate data. H.R. 938 - Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019: Issues regarding discouraging parking of 180-day exclusivity by a first generic applicant that is blocking the approval of other generics. H.R. 1520 - Purple Book Continuity Act of 2019: Issues regarding codifying publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book; Publication and regular updating of the Purple Book electronically on the FDAs website. H.R. 1503 - Orange Book Transparency Act of 2019: Issues regarding ensuring that the Orange Book is accurate and up-to-date, by requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019: Issues regarding brand-name and generic drug manufacturers entering into agreements in which the brand-name drug manufacturer pays the generic manufacturer to keep a generic equivalent off the market. H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 1385 - State Allowance for a Variety of Exchanges (SAVE) Act: Issues regarding federal funds to establish state-based Marketplaces. H.R. 1386 - Expand Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act: Issues regarding funding for Federally-Facilitated Marketplace navigator program; requirements for navigator entities in each state; Health and Human Services ensuring that navigator grants are awarded to entities with demonstrated capacity to carry out the duties specified in the Affordable Care Act. H.R. 987 - Marketing and Outreach Restoration to Empower (MORE) Health Education Act of 2019: Issues related to restoring outreach and enrollment funding to assist consumers in signing up for health care. H.R. 1010 - Issues regarding Short-Term, Limited Duration Insurance. H.R. 986 - Protecting Americans with Preexisting Conditions Act of 2019: Issues regarding rescinding Section 1332 guidance of the ACA promulgated in October 2018. H.R. 1425 - State Health Care Premium Reduction Act: Issues regarding state reinsurance program and providing financial assistance to reduce out-of-pocket costs. H.R. 820 - Public Health Service Act: Issues regarding National Institutes of Health support to collect the medical specimens and information of children with selected cancers that have the least effective treatments. H.R. 2069 - The SPIKE Act, H.R. 2113 - STAR Act, H.R. 2115 - Public Disclosure of Drug Discounts Act, H.R. 2296 - FAIR Drug Pricing Act, H.R. 2376 - Prescription Pricing for the People Act, H.R, 2757 - Creating Lower Cost Alternatives for Your Prescription Drugs Act, S. 657 - Drug Price Transparency (DPT) Act: Issues relating to drug and price transparency. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Regarding all provisions. S. 80, S. 172 - Issues regarding repeal and delay of the health insurer fee. Issues pertaining to surprise billing, including benchmark payments and arbitration models.

H.R. 1781 - Payment Commission Data Act of 2019: Issues regarding providing the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to drug pricing and rebate data. H.R. 938 - Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019: Issues regarding discouraging parking of 180-day exclusivity by a first generic applicant that is blocking the approval of other generics. H.R. 1520 - Purple Book Continuity Act of 2019: Issues regarding codifying publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book; Publication and regular updating of the Purple Book electronically on the FDAs website. H.R. 1503 - Orange Book Transparency Act of 2019: Issues regarding ensuring that the Orange Book is accurate and up-to-date, by requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019: Issues regarding brand-name and generic drug manufacturers entering into agreements in which the brand-name drug manufacturer pays the generic manufacturer to keep a generic equivalent off the market. H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 1385 - State Allowance for a Variety of Exchanges (SAVE) Act: Issues regarding federal funds to establish state-based Marketplaces. H.R. 1386 - Expand Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act: Issues regarding funding for Federally-Facilitated Marketplace navigator program; requirements for navigator entities in each state; Health and Human Services ensuring that navigator grants are awarded to entities with demonstrated capacity to carry out the duties specified in the Affordable Care Act. H.R. 987 - Marketing and Outreach Restoration to Empower (MORE) Health Education Act of 2019: Issues related to restoring outreach and enrollment funding to assist consumers in signing up for health care. H.R. 1010 - Issues regarding Short-Term, Limited Duration Insurance. H.R. 986 - Protecting Americans with Preexisting Conditions Act of 2019: Issues regarding rescinding Section 1332 guidance of the ACA promulgated in October 2018. H.R. 1425 - State Health Care Premium Reduction Act: Issues regarding state reinsurance program and providing financial assistance to reduce out-of-pocket costs. H.R. 820 - Public Health Service Act: Issues regarding National Institutes of Health support to collect the medical specimens and information of children with selected cancers that have the least effective treatments. H.R. 2069 - The SPIKE Act, H.R. 2113 - STAR Act, H.R. 2115 - Public Disclosure of Drug Discounts Act, H.R. 2296 - FAIR Drug Pricing Act, H.R. 2376 - Prescription Pricing for the People Act, H.R, 2757 - Creating Lower Cost Alternatives for Your Prescription Drugs Act, S. 657 - Drug Price Transparency (DPT) Act: Issues relating to drug and price transparency. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Regarding all provisions. S. 80, S. 172 - Issues regarding repeal and delay of the health insurer fee. Issues pertaining to surprise billing, including benchmark payments and arbitration models.

H.R. 1781 - Payment Commission Data Act of 2019: Issues regarding providing the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to drug pricing and rebate data. H.R. 938 - Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019: Issues regarding discouraging parking of 180-day exclusivity by a first generic applicant that is blocking the approval of other generics. H.R. 1520 - Purple Book Continuity Act of 2019: Issues regarding codifying publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book; Publication and regular updating of the Purple Book electronically on the FDAs website. H.R. 1503 - Orange Book Transparency Act of 2019: Issues regarding ensuring that the Orange Book is accurate and up-to-date, by requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019: Issues regarding brand-name and generic drug manufacturers entering into agreements in which the brand-name drug manufacturer pays the generic manufacturer to keep a generic equivalent off the market. H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 1385 - State Allowance for a Variety of Exchanges (SAVE) Act: Issues regarding federal funds to establish state-based Marketplaces. H.R. 1386 - Expand Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act: Issues regarding funding for Federally-Facilitated Marketplace navigator program; requirements for navigator entities in each state; Health and Human Services ensuring that navigator grants are awarded to entities with demonstrated capacity to carry out the duties specified in the Affordable Care Act. H.R. 987 - Marketing and Outreach Restoration to Empower (MORE) Health Education Act of 2019: Issues related to restoring outreach and enrollment funding to assist consumers in signing up for health care. H.R. 1010 - Issues regarding Short-Term, Limited Duration Insurance. H.R. 986 - Protecting Americans with Preexisting Conditions Act of 2019: Issues regarding rescinding Section 1332 guidance of the ACA promulgated in October 2018. H.R. 1425 - State Health Care Premium Reduction Act: Issues regarding state reinsurance program and providing financial assistance to reduce out-of-pocket costs. H.R. 820 - Public Health Service Act: Issues regarding National Institutes of Health support to collect the medical specimens and information of children with selected cancers that have the least effective treatments. 657 - Drug Price Transparency (DPT) Act: Issues relating to drug and price transparency. S. 80, S. 172 - Issues regarding repeal and delay of the health insurer fee. Issues regarding surprise billing, including benchmark payments and arbitration models.

H.R. 1781 - Payment Commission Data Act of 2019: Issues regarding providing the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to drug pricing and rebate data. H.R. 938 - Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019: Issues regarding discouraging parking of 180-day exclusivity by a first generic applicant that is blocking the approval of other generics. H.R. 1520 - Purple Book Continuity Act of 2019: Issues regarding codifying publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book; Publication and regular updating of the Purple Book electronically on the FDAs website. H.R. 1503 - Orange Book Transparency Act of 2019: Issues regarding ensuring that the Orange Book is accurate and up-to-date, by requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019: Issues regarding brand-name and generic drug manufacturers entering into agreements in which the brand-name drug manufacturer pays the generic manufacturer to keep a generic equivalent off the market. H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 1385 - State Allowance for a Variety of Exchanges (SAVE) Act: Issues regarding federal funds to establish state-based Marketplaces. H.R. 1386 - Expand Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act: Issues regarding funding for Federally-Facilitated Marketplace navigator program; requirements for navigator entities in each state; Health and Human Services ensuring that navigator grants are awarded to entities with demonstrated capacity to carry out the duties specified in the Affordable Care Act. H.R. 987 - Marketing and Outreach Restoration to Empower (MORE) Health Education Act of 2019: Issues related to restoring outreach and enrollment funding to assist consumers in signing up for health care. H.R. 1010 - Issues regarding Short-Term, Limited Duration Insurance. H.R. 986 - Protecting Americans with Preexisting Conditions Act of 2019: Issues regarding rescinding Section 1332 guidance of the ACA promulgated in October 2018. H.R. 1425 - State Health Care Premium Reduction Act: Issues regarding state reinsurance program and providing financial assistance to reduce out-of-pocket costs. H.R. 820 - Public Health Service Act: Issues regarding National Institutes of Health support to collect the medical specimens and information of children with selected cancers that have the least effective treatments. 657 - Drug Price Transparency (DPT) Act: Issues relating to drug and price transparency. S. 80, S. 172 - Issues regarding repeal and delay of the health insurer fee. Issues regarding surprise billing, including benchmark payments and arbitration models.

H.R. 1781 - Payment Commission Data Act of 2019: Issues regarding providing the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to drug pricing and rebate data. H.R. 938 - Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019: Issues regarding discouraging parking of 180-day exclusivity by a first generic applicant that is blocking the approval of other generics. H.R. 1520 - Purple Book Continuity Act of 2019: Issues regarding codifying publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book; Publication and regular updating of the Purple Book electronically on the FDAs website. H.R. 1503 - Orange Book Transparency Act of 2019: Issues regarding ensuring that the Orange Book is accurate and up-to-date, by requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019: Issues regarding brand-name and generic drug manufacturers entering into agreements in which the brand-name drug manufacturer pays the generic manufacturer to keep a generic equivalent off the market. H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 1385 - State Allowance for a Variety of Exchanges (SAVE) Act: Issues regarding federal funds to establish state-based Marketplaces. H.R. 1386 - Expand Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act: Issues regarding funding for Federally-Facilitated Marketplace navigator program; requirements for navigator entities in each state; Health and Human Services ensuring that navigator grants are awarded to entities with demonstrated capacity to carry out the duties specified in the Affordable Care Act. H.R. 987 - Marketing and Outreach Restoration to Empower (MORE) Health Education Act of 2019: Issues related to restoring outreach and enrollment funding to assist consumers in signing up for health care. H.R. 1010 - Issues regarding Short-Term, Limited Duration Insurance. H.R. 986 - Protecting Americans with Preexisting Conditions Act of 2019: Issues regarding rescinding Section 1332 guidance of the ACA promulgated in October 2018. H.R. 1425 - State Health Care Premium Reduction Act: Issues regarding state reinsurance program and providing financial assistance to reduce out-of-pocket costs. H.R. 820 - Public Health Service Act: Issues regarding National Institutes of Health support to collect the medical specimens and information of children with selected cancers that have the least effective treatments. 657 - Drug Price Transparency (DPT) Act: Issues relating to drug and price transparency. S. 80, S. 172 - Issues regarding repeal and delay of the health insurer fee. Issues regarding surprise billing, including benchmark payments and arbitration models.

H.R. 1781 - Payment Commission Data Act of 2019: Issues regarding providing the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to drug pricing and rebate data. H.R. 938 - Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019: Issues regarding discouraging parking of 180-day exclusivity by a first generic applicant that is blocking the approval of other generics. H.R. 1520 - Purple Book Continuity Act of 2019: Issues regarding codifying publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book; Publication and regular updating of the Purple Book electronically on the FDAs website. H.R. 1503 - Orange Book Transparency Act of 2019: Issues regarding ensuring that the Orange Book is accurate and up-to-date, by requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019: Issues regarding brand-name and generic drug manufacturers entering into agreements in which the brand-name drug manufacturer pays the generic manufacturer to keep a generic equivalent off the market. H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 1385 - State Allowance for a Variety of Exchanges (SAVE) Act: Issues regarding federal funds to establish state-based Marketplaces. H.R. 1386 - Expand Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act: Issues regarding funding for Federally-Facilitated Marketplace navigator program; requirements for navigator entities in each state; Health and Human Services ensuring that navigator grants are awarded to entities with demonstrated capacity to carry out the duties specified in the Affordable Care Act. H.R. 987 - Marketing and Outreach Restoration to Empower (MORE) Health Education Act of 2019: Issues related to restoring outreach and enrollment funding to assist consumers in signing up for health care. H.R. 1010 - Issues regarding Short-Term, Limited Duration Insurance. H.R. 986 - Protecting Americans with Preexisting Conditions Act of 2019: Issues regarding rescinding Section 1332 guidance of the ACA promulgated in October 2018. H.R. 1425 - State Health Care Premium Reduction Act: Issues regarding state reinsurance program and providing financial assistance to reduce out-of-pocket costs. H.R. 820 - Public Health Service Act: Issues regarding National Institutes of Health support to collect the medical specimens and information of children with selected cancers that have the least effective treatments. H.R. 2069 - The SPIKE Act, H.R. 2113 - STAR Act, H.R. 2115 - Public Disclosure of Drug Discounts Act, H.R. 2296 - FAIR Drug Pricing Act, H.R. 2376 - Prescription Pricing for the People Act, H.R, 2757 - Creating Lower Cost Alternatives for Your Prescription Drugs Act, S. 657 - Drug Price Transparency (DPT) Act: Issues relating to drug and price transparency. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Regarding all provisions. S. 80, S. 172 - Issues regarding repeal and delay of the health insurer fee. Issues pertaining to surprise billing, including benchmark payments and arbitration models.

H.R. 1781 - Payment Commission Data Act of 2019: Issues regarding providing the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to drug pricing and rebate data. H.R. 938 - Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019: Issues regarding discouraging parking of 180-day exclusivity by a first generic applicant that is blocking the approval of other generics. H.R. 1520 - Purple Book Continuity Act of 2019: Issues regarding codifying publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book; Publication and regular updating of the Purple Book electronically on the FDAs website. H.R. 1503 - Orange Book Transparency Act of 2019: Issues regarding ensuring that the Orange Book is accurate and up-to-date, by requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019: Issues regarding brand-name and generic drug manufacturers entering into agreements in which the brand-name drug manufacturer pays the generic manufacturer to keep a generic equivalent off the market. H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 1385 - State Allowance for a Variety of Exchanges (SAVE) Act: Issues regarding federal funds to establish state-based Marketplaces. H.R. 1386 - Expand Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act: Issues regarding funding for Federally-Facilitated Marketplace navigator program; requirements for navigator entities in each state; Health and Human Services ensuring that navigator grants are awarded to entities with demonstrated capacity to carry out the duties specified in the Affordable Care Act. H.R. 987 - Marketing and Outreach Restoration to Empower (MORE) Health Education Act of 2019: Issues related to restoring outreach and enrollment funding to assist consumers in signing up for health care. H.R. 1010 - Issues regarding Short-Term, Limited Duration Insurance. H.R. 986 - Protecting Americans with Preexisting Conditions Act of 2019: Issues regarding rescinding Section 1332 guidance of the ACA promulgated in October 2018. H.R. 1425 - State Health Care Premium Reduction Act: Issues regarding state reinsurance program and providing financial assistance to reduce out-of-pocket costs. H.R. 820 - Public Health Service Act: Issues regarding National Institutes of Health support to collect the medical specimens and information of children with selected cancers that have the least effective treatments. H.R. 2069 - The SPIKE Act, H.R. 2113 - STAR Act, H.R. 2115 - Public Disclosure of Drug Discounts Act, H.R. 2296 - FAIR Drug Pricing Act, H.R. 2376 - Prescription Pricing for the People Act, H.R, 2757 - Creating Lower Cost Alternatives for Your Prescription Drugs Act, S. 657 - Drug Price Transparency (DPT) Act: Issues relating to drug and price transparency. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Regarding all provisions. S. 80, S. 172 - Issues regarding repeal and delay of the health insurer fee. Issues pertaining to surprise billing, including benchmark payments and arbitration models.

H.R. 1781 - Payment Commission Data Act of 2019: Issues regarding providing the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to drug pricing and rebate data. H.R. 938 - Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019: Issues regarding discouraging parking of 180-day exclusivity by a first generic applicant that is blocking the approval of other generics. H.R. 1520 - Purple Book Continuity Act of 2019: Issues regarding codifying publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book; Publication and regular updating of the Purple Book electronically on the FDAs website. H.R. 1503 - Orange Book Transparency Act of 2019: Issues regarding ensuring that the Orange Book is accurate and up-to-date, by requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019: Issues regarding brand-name and generic drug manufacturers entering into agreements in which the brand-name drug manufacturer pays the generic manufacturer to keep a generic equivalent off the market. H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 1385 - State Allowance for a Variety of Exchanges (SAVE) Act: Issues regarding federal funds to establish state-based Marketplaces. H.R. 1386 - Expand Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act: Issues regarding funding for Federally-Facilitated Marketplace navigator program; requirements for navigator entities in each state; Health and Human Services ensuring that navigator grants are awarded to entities with demonstrated capacity to carry out the duties specified in the Affordable Care Act. H.R. 987 - Marketing and Outreach Restoration to Empower (MORE) Health Education Act of 2019: Issues related to restoring outreach and enrollment funding to assist consumers in signing up for health care. H.R. 1010 - Issues regarding Short-Term, Limited Duration Insurance. H.R. 986 - Protecting Americans with Preexisting Conditions Act of 2019: Issues regarding rescinding Section 1332 guidance of the ACA promulgated in October 2018. H.R. 1425 - State Health Care Premium Reduction Act: Issues regarding state reinsurance program and providing financial assistance to reduce out-of-pocket costs. H.R. 820 - Public Health Service Act: Issues regarding National Institutes of Health support to collect the medical specimens and information of children with selected cancers that have the least effective treatments. H.R. 2069 - The SPIKE Act, H.R. 2113 - STAR Act, H.R. 2115 - Public Disclosure of Drug Discounts Act, H.R. 2296 - FAIR Drug Pricing Act, H.R. 2376 - Prescription Pricing for the People Act, H.R, 2757 - Creating Lower Cost Alternatives for Your Prescription Drugs Act, S. 657 - Drug Price Transparency (DPT) Act: Issues relating to drug and price transparency. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Regarding all provisions. S. 80, S. 172 - Issues regarding repeal and delay of the health insurer fee. Issues pertaining to surprise billing, including benchmark payments and arbitration models.

H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Issues related to rural health access; health equity; Medicare Advantage; Medicaid Rebates; Medicaid Expansion; Rate Notice and Call Letter; Medicare Part D; NBPP, Part D Donut Hole; Privacy; Universal Coverage. H.R. 259, Medicaid Extenders Act of 2019, H.R. 4378, Continuing Appropriations Act of 2020: Issues related to Medicaid extension. HR 1398, S. 172 - Health Insurance Tax Relief Act of 2019, S. 80 - Jobs and Premium Protection Act; Issues related to repeal and delay the health insurer fee. Issues related to the Affordable Care Act reinsurance/stabilization. H.R. 861 - End Surprise Billing Act, HR 3630 - No Surprises Act, H.R. 3502 - Protecting People from Surprise Medical Bills Act; Issues relating to surprise billing, including benchmark payments, arbitration models, and out of network billing. S. 916 - MOMMAs Act, H.R. 2602, S. 1343 - MOMMIES Act, HR 4996 - Helping Medicaid Offer Maternity Services Act of 2019: Issues related to options for states to extend coverage for pregnant women eligible for Medicaid via the pregnancy pathway to 365 days, Minority Maternity Care, Social Determinants of Health. S. 657 - Drug Price Transparency (DPT) Act, S. 2543 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug and price transparency. H.R. 3- Lower Drug Costs Now Act of 2019, S. 102 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug costs and prescription rebates. Issues relating to drug and price transparency, including the Administrations rule on interoperability and Executive order on transparency.

H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Issues related to rural health access; health equity; Medicare Advantage; Medicaid Rebates; Medicaid Expansion; Rate Notice and Call Letter; Medicare Part D; NBPP, Part D Donut Hole; Privacy; Universal Coverage. H.R. 259, Medicaid Extenders Act of 2019, H.R. 4378, Continuing Appropriations Act of 2020: Issues related to Medicaid extension. HR 1398, S. 172 - Health Insurance Tax Relief Act of 2019, S. 80 - Jobs and Premium Protection Act; Issues related to repeal and delay the health insurer fee. Issues related to the Affordable Care Act reinsurance/stabilization. H.R. 861 - End Surprise Billing Act, HR 3630 - No Surprises Act, H.R. 3502 - Protecting People from Surprise Medical Bills Act; Issues relating to surprise billing, including benchmark payments, arbitration models, and out of network billing. S. 916 - MOMMAs Act, H.R. 2602, S. 1343 - MOMMIES Act, HR 4996 - Helping Medicaid Offer Maternity Services Act of 2019: Issues related to options for states to extend coverage for pregnant women eligible for Medicaid via the pregnancy pathway to 365 days, Minority Maternity Care, Social Determinants of Health. S. 657 - Drug Price Transparency (DPT) Act, S. 2543 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug and price transparency. H.R. 3- Lower Drug Costs Now Act of 2019, S. 102 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug costs and prescription rebates. Issues relating to drug and price transparency, including the Administrations rule on interoperability and Executive order on transparency.

H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Issues related to rural health access; health equity; Medicare Advantage; Medicaid Rebates; Medicaid Expansion; Rate Notice and Call Letter; Medicare Part D; NBPP, Part D Donut Hole; Privacy; Universal Coverage. H.R. 259, Medicaid Extenders Act of 2019, H.R. 4378, Continuing Appropriations Act of 2020: Issues related to Medicaid extension. HR 1398, S. 172 - Health Insurance Tax Relief Act of 2019, S. 80 - Jobs and Premium Protection Act; Issues related to repeal and delay the health insurer fee. Issues related to the Affordable Care Act reinsurance/stabilization. H.R. 861 - End Surprise Billing Act, HR 3630 - No Surprises Act, H.R. 3502 - Protecting People from Surprise Medical Bills Act; Issues relating to surprise billing, including benchmark payments, arbitration models, and out of network billing. S. 916 - MOMMAs Act, H.R. 2602, S. 1343 - MOMMIES Act, HR 4996 - Helping Medicaid Offer Maternity Services Act of 2019: Issues related to options for states to extend coverage for pregnant women eligible for Medicaid via the pregnancy pathway to 365 days, Minority Maternity Care, Social Determinants of Health. S. 657 - Drug Price Transparency (DPT) Act, S. 2543 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug and price transparency. H.R. 3- Lower Drug Costs Now Act of 2019, S. 102 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug costs and prescription rebates. Issues relating to drug and price transparency, including the Administrations rule on interoperability and Executive order on transparency.

H.R. 1781 - Payment Commission Data Act of 2019: Issues regarding providing the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to drug pricing and rebate data. H.R. 938 - Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019: Issues regarding discouraging parking of 180-day exclusivity by a first generic applicant that is blocking the approval of other generics. H.R. 1520 - Purple Book Continuity Act of 2019: Issues regarding codifying publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book; Publication and regular updating of the Purple Book electronically on the FDAs website. H.R. 1503 - Orange Book Transparency Act of 2019: Issues regarding ensuring that the Orange Book is accurate and up-to-date, by requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019: Issues regarding brand-name and generic drug manufacturers entering into agreements in which the brand-name drug manufacturer pays the generic manufacturer to keep a generic equivalent off the market. H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 1385 - State Allowance for a Variety of Exchanges (SAVE) Act: Issues regarding federal funds to establish state-based Marketplaces. H.R. 1386 - Expand Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act: Issues regarding funding for Federally-Facilitated Marketplace navigator program; requirements for navigator entities in each state; Health and Human Services ensuring that navigator grants are awarded to entities with demonstrated capacity to carry out the duties specified in the Affordable Care Act. H.R. 987 - Marketing and Outreach Restoration to Empower (MORE) Health Education Act of 2019: Issues related to restoring outreach and enrollment funding to assist consumers in signing up for health care. H.R. 1010 - Issues regarding Short-Term, Limited Duration Insurance. H.R. 986 - Protecting Americans with Preexisting Conditions Act of 2019: Issues regarding rescinding Section 1332 guidance of the ACA promulgated in October 2018. H.R. 1425 - State Health Care Premium Reduction Act: Issues regarding state reinsurance program and providing financial assistance to reduce out-of-pocket costs. H.R. 820 - Public Health Service Act: Issues regarding National Institutes of Health support to collect the medical specimens and information of children with selected cancers that have the least effective treatments. 657 - Drug Price Transparency (DPT) Act: Issues relating to drug and price transparency. S. 80, S. 172 - Issues regarding repeal and delay of the health insurer fee. Issues regarding surprise billing, including benchmark payments and arbitration models.

H.R. 1781 - Payment Commission Data Act of 2019: Issues regarding providing the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to drug pricing and rebate data. H.R. 938 - Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019: Issues regarding discouraging parking of 180-day exclusivity by a first generic applicant that is blocking the approval of other generics. H.R. 1520 - Purple Book Continuity Act of 2019: Issues regarding codifying publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book; Publication and regular updating of the Purple Book electronically on the FDAs website. H.R. 1503 - Orange Book Transparency Act of 2019: Issues regarding ensuring that the Orange Book is accurate and up-to-date, by requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019: Issues regarding brand-name and generic drug manufacturers entering into agreements in which the brand-name drug manufacturer pays the generic manufacturer to keep a generic equivalent off the market. H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 1385 - State Allowance for a Variety of Exchanges (SAVE) Act: Issues regarding federal funds to establish state-based Marketplaces. H.R. 1386 - Expand Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act: Issues regarding funding for Federally-Facilitated Marketplace navigator program; requirements for navigator entities in each state; Health and Human Services ensuring that navigator grants are awarded to entities with demonstrated capacity to carry out the duties specified in the Affordable Care Act. H.R. 987 - Marketing and Outreach Restoration to Empower (MORE) Health Education Act of 2019: Issues related to restoring outreach and enrollment funding to assist consumers in signing up for health care. H.R. 1010 - Issues regarding Short-Term, Limited Duration Insurance. H.R. 986 - Protecting Americans with Preexisting Conditions Act of 2019: Issues regarding rescinding Section 1332 guidance of the ACA promulgated in October 2018. H.R. 1425 - State Health Care Premium Reduction Act: Issues regarding state reinsurance program and providing financial assistance to reduce out-of-pocket costs. H.R. 820 - Public Health Service Act: Issues regarding National Institutes of Health support to collect the medical specimens and information of children with selected cancers that have the least effective treatments. H.R. 2069 - The SPIKE Act, H.R. 2113 - STAR Act, H.R. 2115 - Public Disclosure of Drug Discounts Act, H.R. 2296 - FAIR Drug Pricing Act, H.R. 2376 - Prescription Pricing for the People Act, H.R, 2757 - Creating Lower Cost Alternatives for Your Prescription Drugs Act, S. 657 - Drug Price Transparency (DPT) Act: Issues relating to drug and price transparency. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Regarding all provisions. S. 80, S. 172 - Issues regarding repeal and delay of the health insurer fee. Issues pertaining to surprise billing, including benchmark payments and arbitration models.

H.R. 1781 - Payment Commission Data Act of 2019: Issues regarding providing the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to drug pricing and rebate data. H.R. 938 - Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019: Issues regarding discouraging parking of 180-day exclusivity by a first generic applicant that is blocking the approval of other generics. H.R. 1520 - Purple Book Continuity Act of 2019: Issues regarding codifying publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book; Publication and regular updating of the Purple Book electronically on the FDAs website. H.R. 1503 - Orange Book Transparency Act of 2019: Issues regarding ensuring that the Orange Book is accurate and up-to-date, by requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019: Issues regarding brand-name and generic drug manufacturers entering into agreements in which the brand-name drug manufacturer pays the generic manufacturer to keep a generic equivalent off the market. H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 1385 - State Allowance for a Variety of Exchanges (SAVE) Act: Issues regarding federal funds to establish state-based Marketplaces. H.R. 1386 - Expand Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act: Issues regarding funding for Federally-Facilitated Marketplace navigator program; requirements for navigator entities in each state; Health and Human Services ensuring that navigator grants are awarded to entities with demonstrated capacity to carry out the duties specified in the Affordable Care Act. H.R. 987 - Marketing and Outreach Restoration to Empower (MORE) Health Education Act of 2019: Issues related to restoring outreach and enrollment funding to assist consumers in signing up for health care. H.R. 1010 - Issues regarding Short-Term, Limited Duration Insurance. H.R. 986 - Protecting Americans with Preexisting Conditions Act of 2019: Issues regarding rescinding Section 1332 guidance of the ACA promulgated in October 2018. H.R. 1425 - State Health Care Premium Reduction Act: Issues regarding state reinsurance program and providing financial assistance to reduce out-of-pocket costs. H.R. 820 - Public Health Service Act: Issues regarding National Institutes of Health support to collect the medical specimens and information of children with selected cancers that have the least effective treatments. H.R. 2069 - The SPIKE Act, H.R. 2113 - STAR Act, H.R. 2115 - Public Disclosure of Drug Discounts Act, H.R. 2296 - FAIR Drug Pricing Act, H.R. 2376 - Prescription Pricing for the People Act, H.R, 2757 - Creating Lower Cost Alternatives for Your Prescription Drugs Act, S. 657 - Drug Price Transparency (DPT) Act: Issues relating to drug and price transparency. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Regarding all provisions. S. 80, S. 172 - Issues regarding repeal and delay of the health insurer fee. Issues pertaining to surprise billing, including benchmark payments and arbitration models.

H.R. 1781 - Payment Commission Data Act of 2019: Issues regarding providing the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to drug pricing and rebate data. H.R. 938 - Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019: Issues regarding discouraging parking of 180-day exclusivity by a first generic applicant that is blocking the approval of other generics. H.R. 1520 - Purple Book Continuity Act of 2019: Issues regarding codifying publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book; Publication and regular updating of the Purple Book electronically on the FDAs website. H.R. 1503 - Orange Book Transparency Act of 2019: Issues regarding ensuring that the Orange Book is accurate and up-to-date, by requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019: Issues regarding brand-name and generic drug manufacturers entering into agreements in which the brand-name drug manufacturer pays the generic manufacturer to keep a generic equivalent off the market. H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 1385 - State Allowance for a Variety of Exchanges (SAVE) Act: Issues regarding federal funds to establish state-based Marketplaces. H.R. 1386 - Expand Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act: Issues regarding funding for Federally-Facilitated Marketplace navigator program; requirements for navigator entities in each state; Health and Human Services ensuring that navigator grants are awarded to entities with demonstrated capacity to carry out the duties specified in the Affordable Care Act. H.R. 987 - Marketing and Outreach Restoration to Empower (MORE) Health Education Act of 2019: Issues related to restoring outreach and enrollment funding to assist consumers in signing up for health care. H.R. 1010 - Issues regarding Short-Term, Limited Duration Insurance. H.R. 986 - Protecting Americans with Preexisting Conditions Act of 2019: Issues regarding rescinding Section 1332 guidance of the ACA promulgated in October 2018. H.R. 1425 - State Health Care Premium Reduction Act: Issues regarding state reinsurance program and providing financial assistance to reduce out-of-pocket costs. H.R. 820 - Public Health Service Act: Issues regarding National Institutes of Health support to collect the medical specimens and information of children with selected cancers that have the least effective treatments. H.R. 2069 - The SPIKE Act, H.R. 2113 - STAR Act, H.R. 2115 - Public Disclosure of Drug Discounts Act, H.R. 2296 - FAIR Drug Pricing Act, H.R. 2376 - Prescription Pricing for the People Act, H.R, 2757 - Creating Lower Cost Alternatives for Your Prescription Drugs Act, S. 657 - Drug Price Transparency (DPT) Act: Issues relating to drug and price transparency. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Regarding all provisions. S. 80, S. 172 - Issues regarding repeal and delay of the health insurer fee. Issues pertaining to surprise billing, including benchmark payments and arbitration models.

H.R. 1781 - Payment Commission Data Act of 2019: Issues regarding providing the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to drug pricing and rebate data. H.R. 938 - Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019: Issues regarding discouraging parking of 180-day exclusivity by a first generic applicant that is blocking the approval of other generics. H.R. 1520 - Purple Book Continuity Act of 2019: Issues regarding codifying publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book; Publication and regular updating of the Purple Book electronically on the FDAs website. H.R. 1503 - Orange Book Transparency Act of 2019: Issues regarding ensuring that the Orange Book is accurate and up-to-date, by requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019: Issues regarding brand-name and generic drug manufacturers entering into agreements in which the brand-name drug manufacturer pays the generic manufacturer to keep a generic equivalent off the market. H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 1385 - State Allowance for a Variety of Exchanges (SAVE) Act: Issues regarding federal funds to establish state-based Marketplaces. H.R. 1386 - Expand Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act: Issues regarding funding for Federally-Facilitated Marketplace navigator program; requirements for navigator entities in each state; Health and Human Services ensuring that navigator grants are awarded to entities with demonstrated capacity to carry out the duties specified in the Affordable Care Act. H.R. 987 - Marketing and Outreach Restoration to Empower (MORE) Health Education Act of 2019: Issues related to restoring outreach and enrollment funding to assist consumers in signing up for health care. H.R. 1010 - Issues regarding Short-Term, Limited Duration Insurance. H.R. 986 - Protecting Americans with Preexisting Conditions Act of 2019: Issues regarding rescinding Section 1332 guidance of the ACA promulgated in October 2018. H.R. 1425 - State Health Care Premium Reduction Act: Issues regarding state reinsurance program and providing financial assistance to reduce out-of-pocket costs. H.R. 820 - Public Health Service Act: Issues regarding National Institutes of Health support to collect the medical specimens and information of children with selected cancers that have the least effective treatments. 657 - Drug Price Transparency (DPT) Act: Issues relating to drug and price transparency. S. 80, S. 172 - Issues regarding repeal and delay of the health insurer fee. Issues regarding surprise billing, including benchmark payments and arbitration models.

H.R. 1781 - Payment Commission Data Act of 2019: Issues regarding providing the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to drug pricing and rebate data. H.R. 938 - Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019: Issues regarding discouraging parking of 180-day exclusivity by a first generic applicant that is blocking the approval of other generics. H.R. 1520 - Purple Book Continuity Act of 2019: Issues regarding codifying publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book; Publication and regular updating of the Purple Book electronically on the FDAs website. H.R. 1503 - Orange Book Transparency Act of 2019: Issues regarding ensuring that the Orange Book is accurate and up-to-date, by requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019: Issues regarding brand-name and generic drug manufacturers entering into agreements in which the brand-name drug manufacturer pays the generic manufacturer to keep a generic equivalent off the market. H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 1385 - State Allowance for a Variety of Exchanges (SAVE) Act: Issues regarding federal funds to establish state-based Marketplaces. H.R. 1386 - Expand Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act: Issues regarding funding for Federally-Facilitated Marketplace navigator program; requirements for navigator entities in each state; Health and Human Services ensuring that navigator grants are awarded to entities with demonstrated capacity to carry out the duties specified in the Affordable Care Act. H.R. 987 - Marketing and Outreach Restoration to Empower (MORE) Health Education Act of 2019: Issues related to restoring outreach and enrollment funding to assist consumers in signing up for health care. H.R. 1010 - Issues regarding Short-Term, Limited Duration Insurance. H.R. 986 - Protecting Americans with Preexisting Conditions Act of 2019: Issues regarding rescinding Section 1332 guidance of the ACA promulgated in October 2018. H.R. 1425 - State Health Care Premium Reduction Act: Issues regarding state reinsurance program and providing financial assistance to reduce out-of-pocket costs. H.R. 820 - Public Health Service Act: Issues regarding National Institutes of Health support to collect the medical specimens and information of children with selected cancers that have the least effective treatments. 657 - Drug Price Transparency (DPT) Act: Issues relating to drug and price transparency. S. 80, S. 172 - Issues regarding repeal and delay of the health insurer fee. Issues regarding surprise billing, including benchmark payments and arbitration models.

H.R. 1781 - Payment Commission Data Act of 2019: Issues regarding providing the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to drug pricing and rebate data. H.R. 938 - Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019: Issues regarding discouraging parking of 180-day exclusivity by a first generic applicant that is blocking the approval of other generics. H.R. 1520 - Purple Book Continuity Act of 2019: Issues regarding codifying publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book; Publication and regular updating of the Purple Book electronically on the FDAs website. H.R. 1503 - Orange Book Transparency Act of 2019: Issues regarding ensuring that the Orange Book is accurate and up-to-date, by requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019: Issues regarding brand-name and generic drug manufacturers entering into agreements in which the brand-name drug manufacturer pays the generic manufacturer to keep a generic equivalent off the market. H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 1385 - State Allowance for a Variety of Exchanges (SAVE) Act: Issues regarding federal funds to establish state-based Marketplaces. H.R. 1386 - Expand Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act: Issues regarding funding for Federally-Facilitated Marketplace navigator program; requirements for navigator entities in each state; Health and Human Services ensuring that navigator grants are awarded to entities with demonstrated capacity to carry out the duties specified in the Affordable Care Act. H.R. 987 - Marketing and Outreach Restoration to Empower (MORE) Health Education Act of 2019: Issues related to restoring outreach and enrollment funding to assist consumers in signing up for health care. H.R. 1010 - Issues regarding Short-Term, Limited Duration Insurance. H.R. 986 - Protecting Americans with Preexisting Conditions Act of 2019: Issues regarding rescinding Section 1332 guidance of the ACA promulgated in October 2018. H.R. 1425 - State Health Care Premium Reduction Act: Issues regarding state reinsurance program and providing financial assistance to reduce out-of-pocket costs. H.R. 820 - Public Health Service Act: Issues regarding National Institutes of Health support to collect the medical specimens and information of children with selected cancers that have the least effective treatments. 657 - Drug Price Transparency (DPT) Act: Issues relating to drug and price transparency. S. 80, S. 172 - Issues regarding repeal and delay of the health insurer fee. Issues regarding surprise billing, including benchmark payments and arbitration models.

H.R. 1781 - Payment Commission Data Act of 2019: Issues regarding providing the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to drug pricing and rebate data. H.R. 938 - Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019: Issues regarding discouraging parking of 180-day exclusivity by a first generic applicant that is blocking the approval of other generics. H.R. 1520 - Purple Book Continuity Act of 2019: Issues regarding codifying publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book; Publication and regular updating of the Purple Book electronically on the FDAs website. H.R. 1503 - Orange Book Transparency Act of 2019: Issues regarding ensuring that the Orange Book is accurate and up-to-date, by requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019: Issues regarding brand-name and generic drug manufacturers entering into agreements in which the brand-name drug manufacturer pays the generic manufacturer to keep a generic equivalent off the market. H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 1385 - State Allowance for a Variety of Exchanges (SAVE) Act: Issues regarding federal funds to establish state-based Marketplaces. H.R. 1386 - Expand Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act: Issues regarding funding for Federally-Facilitated Marketplace navigator program; requirements for navigator entities in each state; Health and Human Services ensuring that navigator grants are awarded to entities with demonstrated capacity to carry out the duties specified in the Affordable Care Act. H.R. 987 - Marketing and Outreach Restoration to Empower (MORE) Health Education Act of 2019: Issues related to restoring outreach and enrollment funding to assist consumers in signing up for health care. H.R. 1010 - Issues regarding Short-Term, Limited Duration Insurance. H.R. 986 - Protecting Americans with Preexisting Conditions Act of 2019: Issues regarding rescinding Section 1332 guidance of the ACA promulgated in October 2018. H.R. 1425 - State Health Care Premium Reduction Act: Issues regarding state reinsurance program and providing financial assistance to reduce out-of-pocket costs. H.R. 820 - Public Health Service Act: Issues regarding National Institutes of Health support to collect the medical specimens and information of children with selected cancers that have the least effective treatments. H.R. 2069 - The SPIKE Act, H.R. 2113 - STAR Act, H.R. 2115 - Public Disclosure of Drug Discounts Act, H.R. 2296 - FAIR Drug Pricing Act, H.R. 2376 - Prescription Pricing for the People Act, H.R, 2757 - Creating Lower Cost Alternatives for Your Prescription Drugs Act, S. 657 - Drug Price Transparency (DPT) Act: Issues relating to drug and price transparency. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Regarding all provisions. S. 80, S. 172 - Issues regarding repeal and delay of the health insurer fee. Issues pertaining to surprise billing, including benchmark payments and arbitration models.

H.R. 1781 - Payment Commission Data Act of 2019: Issues regarding providing the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to drug pricing and rebate data. H.R. 938 - Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019: Issues regarding discouraging parking of 180-day exclusivity by a first generic applicant that is blocking the approval of other generics. H.R. 1520 - Purple Book Continuity Act of 2019: Issues regarding codifying publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book; Publication and regular updating of the Purple Book electronically on the FDAs website. H.R. 1503 - Orange Book Transparency Act of 2019: Issues regarding ensuring that the Orange Book is accurate and up-to-date, by requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019: Issues regarding brand-name and generic drug manufacturers entering into agreements in which the brand-name drug manufacturer pays the generic manufacturer to keep a generic equivalent off the market. H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 1385 - State Allowance for a Variety of Exchanges (SAVE) Act: Issues regarding federal funds to establish state-based Marketplaces. H.R. 1386 - Expand Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act: Issues regarding funding for Federally-Facilitated Marketplace navigator program; requirements for navigator entities in each state; Health and Human Services ensuring that navigator grants are awarded to entities with demonstrated capacity to carry out the duties specified in the Affordable Care Act. H.R. 987 - Marketing and Outreach Restoration to Empower (MORE) Health Education Act of 2019: Issues related to restoring outreach and enrollment funding to assist consumers in signing up for health care. H.R. 1010 - Issues regarding Short-Term, Limited Duration Insurance. H.R. 986 - Protecting Americans with Preexisting Conditions Act of 2019: Issues regarding rescinding Section 1332 guidance of the ACA promulgated in October 2018. H.R. 1425 - State Health Care Premium Reduction Act: Issues regarding state reinsurance program and providing financial assistance to reduce out-of-pocket costs. H.R. 820 - Public Health Service Act: Issues regarding National Institutes of Health support to collect the medical specimens and information of children with selected cancers that have the least effective treatments. H.R. 2069 - The SPIKE Act, H.R. 2113 - STAR Act, H.R. 2115 - Public Disclosure of Drug Discounts Act, H.R. 2296 - FAIR Drug Pricing Act, H.R. 2376 - Prescription Pricing for the People Act, H.R, 2757 - Creating Lower Cost Alternatives for Your Prescription Drugs Act, S. 657 - Drug Price Transparency (DPT) Act: Issues relating to drug and price transparency. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Regarding all provisions. S. 80, S. 172 - Issues regarding repeal and delay of the health insurer fee. Issues pertaining to surprise billing, including benchmark payments and arbitration models.

H.R. 1781 - Payment Commission Data Act of 2019: Issues regarding providing the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to drug pricing and rebate data. H.R. 938 - Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019: Issues regarding discouraging parking of 180-day exclusivity by a first generic applicant that is blocking the approval of other generics. H.R. 1520 - Purple Book Continuity Act of 2019: Issues regarding codifying publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book; Publication and regular updating of the Purple Book electronically on the FDAs website. H.R. 1503 - Orange Book Transparency Act of 2019: Issues regarding ensuring that the Orange Book is accurate and up-to-date, by requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019: Issues regarding brand-name and generic drug manufacturers entering into agreements in which the brand-name drug manufacturer pays the generic manufacturer to keep a generic equivalent off the market. H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 1385 - State Allowance for a Variety of Exchanges (SAVE) Act: Issues regarding federal funds to establish state-based Marketplaces. H.R. 1386 - Expand Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act: Issues regarding funding for Federally-Facilitated Marketplace navigator program; requirements for navigator entities in each state; Health and Human Services ensuring that navigator grants are awarded to entities with demonstrated capacity to carry out the duties specified in the Affordable Care Act. H.R. 987 - Marketing and Outreach Restoration to Empower (MORE) Health Education Act of 2019: Issues related to restoring outreach and enrollment funding to assist consumers in signing up for health care. H.R. 1010 - Issues regarding Short-Term, Limited Duration Insurance. H.R. 986 - Protecting Americans with Preexisting Conditions Act of 2019: Issues regarding rescinding Section 1332 guidance of the ACA promulgated in October 2018. H.R. 1425 - State Health Care Premium Reduction Act: Issues regarding state reinsurance program and providing financial assistance to reduce out-of-pocket costs. H.R. 820 - Public Health Service Act: Issues regarding National Institutes of Health support to collect the medical specimens and information of children with selected cancers that have the least effective treatments. H.R. 2069 - The SPIKE Act, H.R. 2113 - STAR Act, H.R. 2115 - Public Disclosure of Drug Discounts Act, H.R. 2296 - FAIR Drug Pricing Act, H.R. 2376 - Prescription Pricing for the People Act, H.R, 2757 - Creating Lower Cost Alternatives for Your Prescription Drugs Act, S. 657 - Drug Price Transparency (DPT) Act: Issues relating to drug and price transparency. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Regarding all provisions. S. 80, S. 172 - Issues regarding repeal and delay of the health insurer fee. Issues pertaining to surprise billing, including benchmark payments and arbitration models.

H.R. 1781 - Payment Commission Data Act of 2019: Issues regarding providing the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to drug pricing and rebate data. H.R. 938 - Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019: Issues regarding discouraging parking of 180-day exclusivity by a first generic applicant that is blocking the approval of other generics. H.R. 1520 - Purple Book Continuity Act of 2019: Issues regarding codifying publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book; Publication and regular updating of the Purple Book electronically on the FDAs website. H.R. 1503 - Orange Book Transparency Act of 2019: Issues regarding ensuring that the Orange Book is accurate and up-to-date, by requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019: Issues regarding brand-name and generic drug manufacturers entering into agreements in which the brand-name drug manufacturer pays the generic manufacturer to keep a generic equivalent off the market. H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 1385 - State Allowance for a Variety of Exchanges (SAVE) Act: Issues regarding federal funds to establish state-based Marketplaces. H.R. 1386 - Expand Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act: Issues regarding funding for Federally-Facilitated Marketplace navigator program; requirements for navigator entities in each state; Health and Human Services ensuring that navigator grants are awarded to entities with demonstrated capacity to carry out the duties specified in the Affordable Care Act. H.R. 987 - Marketing and Outreach Restoration to Empower (MORE) Health Education Act of 2019: Issues related to restoring outreach and enrollment funding to assist consumers in signing up for health care. H.R. 1010 - Issues regarding Short-Term, Limited Duration Insurance. H.R. 986 - Protecting Americans with Preexisting Conditions Act of 2019: Issues regarding rescinding Section 1332 guidance of the ACA promulgated in October 2018. H.R. 1425 - State Health Care Premium Reduction Act: Issues regarding state reinsurance program and providing financial assistance to reduce out-of-pocket costs. H.R. 820 - Public Health Service Act: Issues regarding National Institutes of Health support to collect the medical specimens and information of children with selected cancers that have the least effective treatments. H.R. 2069 - The SPIKE Act, H.R. 2113 - STAR Act, H.R. 2115 - Public Disclosure of Drug Discounts Act, H.R. 2296 - FAIR Drug Pricing Act, H.R. 2376 - Prescription Pricing for the People Act, H.R, 2757 - Creating Lower Cost Alternatives for Your Prescription Drugs Act, S. 657 - Drug Price Transparency (DPT) Act: Issues relating to drug and price transparency. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Regarding all provisions. S. 80, S. 172 - Issues regarding repeal and delay of the health insurer fee. Issues pertaining to surprise billing, including benchmark payments and arbitration models.

H.R. 1781 - Payment Commission Data Act of 2019: Issues regarding providing the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to drug pricing and rebate data. H.R. 938 - Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019: Issues regarding discouraging parking of 180-day exclusivity by a first generic applicant that is blocking the approval of other generics. H.R. 1520 - Purple Book Continuity Act of 2019: Issues regarding codifying publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book; Publication and regular updating of the Purple Book electronically on the FDAs website. H.R. 1503 - Orange Book Transparency Act of 2019: Issues regarding ensuring that the Orange Book is accurate and up-to-date, by requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019: Issues regarding brand-name and generic drug manufacturers entering into agreements in which the brand-name drug manufacturer pays the generic manufacturer to keep a generic equivalent off the market. H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 1385 - State Allowance for a Variety of Exchanges (SAVE) Act: Issues regarding federal funds to establish state-based Marketplaces. H.R. 1386 - Expand Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act: Issues regarding funding for Federally-Facilitated Marketplace navigator program; requirements for navigator entities in each state; Health and Human Services ensuring that navigator grants are awarded to entities with demonstrated capacity to carry out the duties specified in the Affordable Care Act. H.R. 987 - Marketing and Outreach Restoration to Empower (MORE) Health Education Act of 2019: Issues related to restoring outreach and enrollment funding to assist consumers in signing up for health care. H.R. 1010 - Issues regarding Short-Term, Limited Duration Insurance. H.R. 986 - Protecting Americans with Preexisting Conditions Act of 2019: Issues regarding rescinding Section 1332 guidance of the ACA promulgated in October 2018. H.R. 1425 - State Health Care Premium Reduction Act: Issues regarding state reinsurance program and providing financial assistance to reduce out-of-pocket costs. H.R. 820 - Public Health Service Act: Issues regarding National Institutes of Health support to collect the medical specimens and information of children with selected cancers that have the least effective treatments. H.R. 2069 - The SPIKE Act, H.R. 2113 - STAR Act, H.R. 2115 - Public Disclosure of Drug Discounts Act, H.R. 2296 - FAIR Drug Pricing Act, H.R. 2376 - Prescription Pricing for the People Act, H.R, 2757 - Creating Lower Cost Alternatives for Your Prescription Drugs Act, S. 657 - Drug Price Transparency (DPT) Act: Issues relating to drug and price transparency. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Regarding all provisions. S. 80, S. 172 - Issues regarding repeal and delay of the health insurer fee. Issues pertaining to surprise billing, including benchmark payments and arbitration models.

H.R. 1781 - Payment Commission Data Act of 2019: Issues regarding providing the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to drug pricing and rebate data. H.R. 938 - Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019: Issues regarding discouraging parking of 180-day exclusivity by a first generic applicant that is blocking the approval of other generics. H.R. 1520 - Purple Book Continuity Act of 2019: Issues regarding codifying publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book; Publication and regular updating of the Purple Book electronically on the FDAs website. H.R. 1503 - Orange Book Transparency Act of 2019: Issues regarding ensuring that the Orange Book is accurate and up-to-date, by requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019: Issues regarding brand-name and generic drug manufacturers entering into agreements in which the brand-name drug manufacturer pays the generic manufacturer to keep a generic equivalent off the market. H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 1385 - State Allowance for a Variety of Exchanges (SAVE) Act: Issues regarding federal funds to establish state-based Marketplaces. H.R. 1386 - Expand Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act: Issues regarding funding for Federally-Facilitated Marketplace navigator program; requirements for navigator entities in each state; Health and Human Services ensuring that navigator grants are awarded to entities with demonstrated capacity to carry out the duties specified in the Affordable Care Act. H.R. 987 - Marketing and Outreach Restoration to Empower (MORE) Health Education Act of 2019: Issues related to restoring outreach and enrollment funding to assist consumers in signing up for health care. H.R. 1010 - Issues regarding Short-Term, Limited Duration Insurance. H.R. 986 - Protecting Americans with Preexisting Conditions Act of 2019: Issues regarding rescinding Section 1332 guidance of the ACA promulgated in October 2018. H.R. 1425 - State Health Care Premium Reduction Act: Issues regarding state reinsurance program and providing financial assistance to reduce out-of-pocket costs. H.R. 820 - Public Health Service Act: Issues regarding National Institutes of Health support to collect the medical specimens and information of children with selected cancers that have the least effective treatments. H.R. 2069 - The SPIKE Act, H.R. 2113 - STAR Act, H.R. 2115 - Public Disclosure of Drug Discounts Act, H.R. 2296 - FAIR Drug Pricing Act, H.R. 2376 - Prescription Pricing for the People Act, H.R, 2757 - Creating Lower Cost Alternatives for Your Prescription Drugs Act, S. 657 - Drug Price Transparency (DPT) Act: Issues relating to drug and price transparency. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Regarding all provisions. S. 80, S. 172 - Issues regarding repeal and delay of the health insurer fee. Issues pertaining to surprise billing, including benchmark payments and arbitration models.

H.R. 1781 - Payment Commission Data Act of 2019: Issues regarding providing the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to drug pricing and rebate data. H.R. 938 - Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019: Issues regarding discouraging parking of 180-day exclusivity by a first generic applicant that is blocking the approval of other generics. H.R. 1520 - Purple Book Continuity Act of 2019: Issues regarding codifying publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book; Publication and regular updating of the Purple Book electronically on the FDAs website. H.R. 1503 - Orange Book Transparency Act of 2019: Issues regarding ensuring that the Orange Book is accurate and up-to-date, by requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019: Issues regarding brand-name and generic drug manufacturers entering into agreements in which the brand-name drug manufacturer pays the generic manufacturer to keep a generic equivalent off the market. H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 1385 - State Allowance for a Variety of Exchanges (SAVE) Act: Issues regarding federal funds to establish state-based Marketplaces. H.R. 1386 - Expand Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act: Issues regarding funding for Federally-Facilitated Marketplace navigator program; requirements for navigator entities in each state; Health and Human Services ensuring that navigator grants are awarded to entities with demonstrated capacity to carry out the duties specified in the Affordable Care Act. H.R. 987 - Marketing and Outreach Restoration to Empower (MORE) Health Education Act of 2019: Issues related to restoring outreach and enrollment funding to assist consumers in signing up for health care. H.R. 1010 - Issues regarding Short-Term, Limited Duration Insurance. H.R. 986 - Protecting Americans with Preexisting Conditions Act of 2019: Issues regarding rescinding Section 1332 guidance of the ACA promulgated in October 2018. H.R. 1425 - State Health Care Premium Reduction Act: Issues regarding state reinsurance program and providing financial assistance to reduce out-of-pocket costs. H.R. 820 - Public Health Service Act: Issues regarding National Institutes of Health support to collect the medical specimens and information of children with selected cancers that have the least effective treatments. 657 - Drug Price Transparency (DPT) Act: Issues relating to drug and price transparency. S. 80, S. 172 - Issues regarding repeal and delay of the health insurer fee. Issues regarding surprise billing, including benchmark payments and arbitration models.

H.R. 1781 - Payment Commission Data Act of 2019: Issues regarding providing the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to drug pricing and rebate data. H.R. 938 - Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019: Issues regarding discouraging parking of 180-day exclusivity by a first generic applicant that is blocking the approval of other generics. H.R. 1520 - Purple Book Continuity Act of 2019: Issues regarding codifying publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book; Publication and regular updating of the Purple Book electronically on the FDAs website. H.R. 1503 - Orange Book Transparency Act of 2019: Issues regarding ensuring that the Orange Book is accurate and up-to-date, by requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019: Issues regarding brand-name and generic drug manufacturers entering into agreements in which the brand-name drug manufacturer pays the generic manufacturer to keep a generic equivalent off the market. H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 1385 - State Allowance for a Variety of Exchanges (SAVE) Act: Issues regarding federal funds to establish state-based Marketplaces. H.R. 1386 - Expand Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act: Issues regarding funding for Federally-Facilitated Marketplace navigator program; requirements for navigator entities in each state; Health and Human Services ensuring that navigator grants are awarded to entities with demonstrated capacity to carry out the duties specified in the Affordable Care Act. H.R. 987 - Marketing and Outreach Restoration to Empower (MORE) Health Education Act of 2019: Issues related to restoring outreach and enrollment funding to assist consumers in signing up for health care. H.R. 1010 - Issues regarding Short-Term, Limited Duration Insurance. H.R. 986 - Protecting Americans with Preexisting Conditions Act of 2019: Issues regarding rescinding Section 1332 guidance of the ACA promulgated in October 2018. H.R. 1425 - State Health Care Premium Reduction Act: Issues regarding state reinsurance program and providing financial assistance to reduce out-of-pocket costs. H.R. 820 - Public Health Service Act: Issues regarding National Institutes of Health support to collect the medical specimens and information of children with selected cancers that have the least effective treatments. 657 - Drug Price Transparency (DPT) Act: Issues relating to drug and price transparency. S. 80, S. 172 - Issues regarding repeal and delay of the health insurer fee. Issues regarding surprise billing, including benchmark payments and arbitration models.

H.R. 1781 - Payment Commission Data Act of 2019: Issues regarding providing the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to drug pricing and rebate data. H.R. 938 - Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019: Issues regarding discouraging parking of 180-day exclusivity by a first generic applicant that is blocking the approval of other generics. H.R. 1520 - Purple Book Continuity Act of 2019: Issues regarding codifying publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book; Publication and regular updating of the Purple Book electronically on the FDAs website. H.R. 1503 - Orange Book Transparency Act of 2019: Issues regarding ensuring that the Orange Book is accurate and up-to-date, by requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019: Issues regarding brand-name and generic drug manufacturers entering into agreements in which the brand-name drug manufacturer pays the generic manufacturer to keep a generic equivalent off the market. H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 1385 - State Allowance for a Variety of Exchanges (SAVE) Act: Issues regarding federal funds to establish state-based Marketplaces. H.R. 1386 - Expand Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act: Issues regarding funding for Federally-Facilitated Marketplace navigator program; requirements for navigator entities in each state; Health and Human Services ensuring that navigator grants are awarded to entities with demonstrated capacity to carry out the duties specified in the Affordable Care Act. H.R. 987 - Marketing and Outreach Restoration to Empower (MORE) Health Education Act of 2019: Issues related to restoring outreach and enrollment funding to assist consumers in signing up for health care. H.R. 1010 - Issues regarding Short-Term, Limited Duration Insurance. H.R. 986 - Protecting Americans with Preexisting Conditions Act of 2019: Issues regarding rescinding Section 1332 guidance of the ACA promulgated in October 2018. H.R. 1425 - State Health Care Premium Reduction Act: Issues regarding state reinsurance program and providing financial assistance to reduce out-of-pocket costs. H.R. 820 - Public Health Service Act: Issues regarding National Institutes of Health support to collect the medical specimens and information of children with selected cancers that have the least effective treatments. 657 - Drug Price Transparency (DPT) Act: Issues relating to drug and price transparency. S. 80, S. 172 - Issues regarding repeal and delay of the health insurer fee. Issues regarding surprise billing, including benchmark payments and arbitration models.

H.R. 1781 - Payment Commission Data Act of 2019: Issues regarding providing the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to drug pricing and rebate data. H.R. 938 - Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019: Issues regarding discouraging parking of 180-day exclusivity by a first generic applicant that is blocking the approval of other generics. H.R. 1520 - Purple Book Continuity Act of 2019: Issues regarding codifying publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book; Publication and regular updating of the Purple Book electronically on the FDAs website. H.R. 1503 - Orange Book Transparency Act of 2019: Issues regarding ensuring that the Orange Book is accurate and up-to-date, by requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019: Issues regarding brand-name and generic drug manufacturers entering into agreements in which the brand-name drug manufacturer pays the generic manufacturer to keep a generic equivalent off the market. H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 1385 - State Allowance for a Variety of Exchanges (SAVE) Act: Issues regarding federal funds to establish state-based Marketplaces. H.R. 1386 - Expand Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act: Issues regarding funding for Federally-Facilitated Marketplace navigator program; requirements for navigator entities in each state; Health and Human Services ensuring that navigator grants are awarded to entities with demonstrated capacity to carry out the duties specified in the Affordable Care Act. H.R. 987 - Marketing and Outreach Restoration to Empower (MORE) Health Education Act of 2019: Issues related to restoring outreach and enrollment funding to assist consumers in signing up for health care. H.R. 1010 - Issues regarding Short-Term, Limited Duration Insurance. H.R. 986 - Protecting Americans with Preexisting Conditions Act of 2019: Issues regarding rescinding Section 1332 guidance of the ACA promulgated in October 2018. H.R. 1425 - State Health Care Premium Reduction Act: Issues regarding state reinsurance program and providing financial assistance to reduce out-of-pocket costs. H.R. 820 - Public Health Service Act: Issues regarding National Institutes of Health support to collect the medical specimens and information of children with selected cancers that have the least effective treatments. H.R. 2069 - The SPIKE Act, H.R. 2113 - STAR Act, H.R. 2115 - Public Disclosure of Drug Discounts Act, H.R. 2296 - FAIR Drug Pricing Act, H.R. 2376 - Prescription Pricing for the People Act, H.R, 2757 - Creating Lower Cost Alternatives for Your Prescription Drugs Act, S. 657 - Drug Price Transparency (DPT) Act: Issues relating to drug and price transparency. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Regarding all provisions. S. 80, S. 172 - Issues regarding repeal and delay of the health insurer fee. Issues pertaining to surprise billing, including benchmark payments and arbitration models.

H.R. 1781 - Payment Commission Data Act of 2019: Issues regarding providing the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to drug pricing and rebate data. H.R. 938 - Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019: Issues regarding discouraging parking of 180-day exclusivity by a first generic applicant that is blocking the approval of other generics. H.R. 1520 - Purple Book Continuity Act of 2019: Issues regarding codifying publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book; Publication and regular updating of the Purple Book electronically on the FDAs website. H.R. 1503 - Orange Book Transparency Act of 2019: Issues regarding ensuring that the Orange Book is accurate and up-to-date, by requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019: Issues regarding brand-name and generic drug manufacturers entering into agreements in which the brand-name drug manufacturer pays the generic manufacturer to keep a generic equivalent off the market. H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 1385 - State Allowance for a Variety of Exchanges (SAVE) Act: Issues regarding federal funds to establish state-based Marketplaces. H.R. 1386 - Expand Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act: Issues regarding funding for Federally-Facilitated Marketplace navigator program; requirements for navigator entities in each state; Health and Human Services ensuring that navigator grants are awarded to entities with demonstrated capacity to carry out the duties specified in the Affordable Care Act. H.R. 987 - Marketing and Outreach Restoration to Empower (MORE) Health Education Act of 2019: Issues related to restoring outreach and enrollment funding to assist consumers in signing up for health care. H.R. 1010 - Issues regarding Short-Term, Limited Duration Insurance. H.R. 986 - Protecting Americans with Preexisting Conditions Act of 2019: Issues regarding rescinding Section 1332 guidance of the ACA promulgated in October 2018. H.R. 1425 - State Health Care Premium Reduction Act: Issues regarding state reinsurance program and providing financial assistance to reduce out-of-pocket costs. H.R. 820 - Public Health Service Act: Issues regarding National Institutes of Health support to collect the medical specimens and information of children with selected cancers that have the least effective treatments. 657 - Drug Price Transparency (DPT) Act: Issues relating to drug and price transparency. S. 80, S. 172 - Issues regarding repeal and delay of the health insurer fee. Issues regarding surprise billing, including benchmark payments and arbitration models.

H.R. 1781 - Payment Commission Data Act of 2019: Issues regarding providing the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to drug pricing and rebate data. H.R. 938 - Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019: Issues regarding discouraging parking of 180-day exclusivity by a first generic applicant that is blocking the approval of other generics. H.R. 1520 - Purple Book Continuity Act of 2019: Issues regarding codifying publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book; Publication and regular updating of the Purple Book electronically on the FDAs website. H.R. 1503 - Orange Book Transparency Act of 2019: Issues regarding ensuring that the Orange Book is accurate and up-to-date, by requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019: Issues regarding brand-name and generic drug manufacturers entering into agreements in which the brand-name drug manufacturer pays the generic manufacturer to keep a generic equivalent off the market. H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 1385 - State Allowance for a Variety of Exchanges (SAVE) Act: Issues regarding federal funds to establish state-based Marketplaces. H.R. 1386 - Expand Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act: Issues regarding funding for Federally-Facilitated Marketplace navigator program; requirements for navigator entities in each state; Health and Human Services ensuring that navigator grants are awarded to entities with demonstrated capacity to carry out the duties specified in the Affordable Care Act. H.R. 987 - Marketing and Outreach Restoration to Empower (MORE) Health Education Act of 2019: Issues related to restoring outreach and enrollment funding to assist consumers in signing up for health care. H.R. 1010 - Issues regarding Short-Term, Limited Duration Insurance. H.R. 986 - Protecting Americans with Preexisting Conditions Act of 2019: Issues regarding rescinding Section 1332 guidance of the ACA promulgated in October 2018. H.R. 1425 - State Health Care Premium Reduction Act: Issues regarding state reinsurance program and providing financial assistance to reduce out-of-pocket costs. H.R. 820 - Public Health Service Act: Issues regarding National Institutes of Health support to collect the medical specimens and information of children with selected cancers that have the least effective treatments. H.R. 2069 - The SPIKE Act, H.R. 2113 - STAR Act, H.R. 2115 - Public Disclosure of Drug Discounts Act, H.R. 2296 - FAIR Drug Pricing Act, H.R. 2376 - Prescription Pricing for the People Act, H.R, 2757 - Creating Lower Cost Alternatives for Your Prescription Drugs Act, S. 657 - Drug Price Transparency (DPT) Act: Issues relating to drug and price transparency. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Regarding all provisions. S. 80, S. 172 - Issues regarding repeal and delay of the health insurer fee. Issues pertaining to surprise billing, including benchmark payments and arbitration models.

H.R. 1781 - Payment Commission Data Act of 2019: Issues regarding providing the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to drug pricing and rebate data. H.R. 938 - Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019: Issues regarding discouraging parking of 180-day exclusivity by a first generic applicant that is blocking the approval of other generics. H.R. 1520 - Purple Book Continuity Act of 2019: Issues regarding codifying publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book; Publication and regular updating of the Purple Book electronically on the FDAs website. H.R. 1503 - Orange Book Transparency Act of 2019: Issues regarding ensuring that the Orange Book is accurate and up-to-date, by requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019: Issues regarding brand-name and generic drug manufacturers entering into agreements in which the brand-name drug manufacturer pays the generic manufacturer to keep a generic equivalent off the market. H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 1385 - State Allowance for a Variety of Exchanges (SAVE) Act: Issues regarding federal funds to establish state-based Marketplaces. H.R. 1386 - Expand Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act: Issues regarding funding for Federally-Facilitated Marketplace navigator program; requirements for navigator entities in each state; Health and Human Services ensuring that navigator grants are awarded to entities with demonstrated capacity to carry out the duties specified in the Affordable Care Act. H.R. 987 - Marketing and Outreach Restoration to Empower (MORE) Health Education Act of 2019: Issues related to restoring outreach and enrollment funding to assist consumers in signing up for health care. H.R. 1010 - Issues regarding Short-Term, Limited Duration Insurance. H.R. 986 - Protecting Americans with Preexisting Conditions Act of 2019: Issues regarding rescinding Section 1332 guidance of the ACA promulgated in October 2018. H.R. 1425 - State Health Care Premium Reduction Act: Issues regarding state reinsurance program and providing financial assistance to reduce out-of-pocket costs. H.R. 820 - Public Health Service Act: Issues regarding National Institutes of Health support to collect the medical specimens and information of children with selected cancers that have the least effective treatments. H.R. 2069 - The SPIKE Act, H.R. 2113 - STAR Act, H.R. 2115 - Public Disclosure of Drug Discounts Act, H.R. 2296 - FAIR Drug Pricing Act, H.R. 2376 - Prescription Pricing for the People Act, H.R, 2757 - Creating Lower Cost Alternatives for Your Prescription Drugs Act, S. 657 - Drug Price Transparency (DPT) Act: Issues relating to drug and price transparency. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Regarding all provisions. S. 80, S. 172 - Issues regarding repeal and delay of the health insurer fee. Issues pertaining to surprise billing, including benchmark payments and arbitration models.

H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Issues related to ACA reinsurance/stabilization; rural health access; health equity; Medicare Advantage; Medicaid Rebates; Medicaid Expansion; Rate Notice and Call Letter; Medicare Part D; NBPP, Part D Donut Hole; Prescription Rebates; Privacy; Universal Coverage. H.R. 3439 - Protecting Access To Information for Effective and Necessary Treatment Act, PATIENT Act: Regarding all provisions. H.R. 861 - End Surprise Billing Act, HR 3630 - No Surprises Act, H.R. 3502 - Protecting People from Surprise Medical Bills Act; Issues relating to surprise billing, including benchmark payments, arbitration models, and out of network billing. H.R. 1897, S. 916 - MOMMAs Act, H.R. 2602, S. 1343 - MOMMIES Act, H.R. 1551 - Quality Care for Moms and Babies Act, H.R. 2902 - Maternal Care Act: Issues related to options for states to extend coverage for pregnant women eligible for Medicaid via the pregnancy pathway to 365 days, Minority Maternity Care, Social Determinants of Health. S. 657 - Drug Price Transparency (DPT) Act, S. 2543 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug and price transparency. H.R. 3- Lower Drug Costs Now Act of 2019, S. 102 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug costs. Centers for Medicare and Medicaid Services 84 FR 39398 - Hospital Outpatient Prospective Payment System (OPPS); EO 13877 / 84 FR 30849 - Improving Price and Quality Transparency in American Healthcare To Put Patients First; Centers for Medicare and Medicaid Services Proposed Rule 84 FR 7610 - Interoperability and Patient Access; Office of National Coordinator for Health Information Technology Proposed Rule 84 FR 7424 - Interoperability, Information Blocking, and the ONC Health IT Certification Program; Issues relating to drug and price transparency.

H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Issues related to ACA reinsurance/stabilization; rural health access; health equity; Medicare Advantage; Medicaid Rebates; Medicaid Expansion; Rate Notice and Call Letter; Medicare Part D; NBPP, Part D Donut Hole; Prescription Rebates; Privacy; Universal Coverage. H.R. 3439 - Protecting Access To Information for Effective and Necessary Treatment Act, PATIENT Act: Regarding all provisions. H.R. 861 - End Surprise Billing Act, HR 3630 - No Surprises Act, H.R. 3502 - Protecting People from Surprise Medical Bills Act; Issues relating to surprise billing, including benchmark payments, arbitration models, and out of network billing. H.R. 1897, S. 916 - MOMMAs Act, H.R. 2602, S. 1343 - MOMMIES Act, H.R. 1551 - Quality Care for Moms and Babies Act, H.R. 2902 - Maternal Care Act: Issues related to options for states to extend coverage for pregnant women eligible for Medicaid via the pregnancy pathway to 365 days, Minority Maternity Care, Social Determinants of Health. S. 657 - Drug Price Transparency (DPT) Act, S. 2543 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug and price transparency. H.R. 3- Lower Drug Costs Now Act of 2019, S. 102 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug costs. Centers for Medicare and Medicaid Services 84 FR 39398 - Hospital Outpatient Prospective Payment System (OPPS); EO 13877 / 84 FR 30849 - Improving Price and Quality Transparency in American Healthcare To Put Patients First; Centers for Medicare and Medicaid Services Proposed Rule 84 FR 7610 - Interoperability and Patient Access; Office of National Coordinator for Health Information Technology Proposed Rule 84 FR 7424 - Interoperability, Information Blocking, and the ONC Health IT Certification Program; Issues relating to drug and price transparency.

H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Issues related to ACA reinsurance/stabilization; rural health access; health equity; Medicare Advantage; Medicaid Rebates; Medicaid Expansion; Rate Notice and Call Letter; Medicare Part D; NBPP, Part D Donut Hole; Prescription Rebates; Privacy; Universal Coverage. H.R. 3439 - Protecting Access To Information for Effective and Necessary Treatment Act, PATIENT Act: Regarding all provisions. H.R. 861 - End Surprise Billing Act, HR 3630 - No Surprises Act, H.R. 3502 - Protecting People from Surprise Medical Bills Act; Issues relating to surprise billing, including benchmark payments, arbitration models, and out of network billing. H.R. 1897, S. 916 - MOMMAs Act, H.R. 2602, S. 1343 - MOMMIES Act, H.R. 1551 - Quality Care for Moms and Babies Act, H.R. 2902 - Maternal Care Act: Issues related to options for states to extend coverage for pregnant women eligible for Medicaid via the pregnancy pathway to 365 days, Minority Maternity Care, Social Determinants of Health. S. 657 - Drug Price Transparency (DPT) Act, S. 2543 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug and price transparency. H.R. 3- Lower Drug Costs Now Act of 2019, S. 102 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug costs. Centers for Medicare and Medicaid Services 84 FR 39398 - Hospital Outpatient Prospective Payment System (OPPS); EO 13877 / 84 FR 30849 - Improving Price and Quality Transparency in American Healthcare To Put Patients First; Centers for Medicare and Medicaid Services Proposed Rule 84 FR 7610 - Interoperability and Patient Access; Office of National Coordinator for Health Information Technology Proposed Rule 84 FR 7424 - Interoperability, Information Blocking, and the ONC Health IT Certification Program; Issues relating to drug and price transparency.

H.R. 1781 - Payment Commission Data Act of 2019: Provisions regarding drug pricing and rebate data, drug costs, Affordable Care Act reinsurance/stabilization, out-of-network billing, rural health access, health equity, Medicare Advantage, Medicaid Rebates, Medicaid Expansion, Rate Notice and Call Letter, Medicare Part D, Notice of Benefit and Payment Parameters, Part D Donut Hole, Prescription Rebates, Privacy.

H.R. 1781 - Payment Commission Data Act of 2019: Issues regarding providing the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to drug pricing and rebate data. H.R. 938 - Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019: Issues regarding discouraging parking of 180-day exclusivity by a first generic applicant that is blocking the approval of other generics. H.R. 1520 - Purple Book Continuity Act of 2019: Issues regarding codifying publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book; Publication and regular updating of the Purple Book electronically on the FDAs website. H.R. 1503 - Orange Book Transparency Act of 2019: Issues regarding ensuring that the Orange Book is accurate and up-to-date, by requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019: Issues regarding brand-name and generic drug manufacturers entering into agreements in which the brand-name drug manufacturer pays the generic manufacturer to keep a generic equivalent off the market. H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 1385 - State Allowance for a Variety of Exchanges (SAVE) Act: Issues regarding federal funds to establish state-based Marketplaces. H.R. 1386 - Expand Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act: Issues regarding funding for Federally-Facilitated Marketplace navigator program; requirements for navigator entities in each state; Health and Human Services ensuring that navigator grants are awarded to entities with demonstrated capacity to carry out the duties specified in the Affordable Care Act. H.R. 987 - Marketing and Outreach Restoration to Empower (MORE) Health Education Act of 2019: Issues related to restoring outreach and enrollment funding to assist consumers in signing up for health care. H.R. 1010 - Issues regarding Short-Term, Limited Duration Insurance. H.R. 986 - Protecting Americans with Preexisting Conditions Act of 2019: Issues regarding rescinding Section 1332 guidance of the ACA promulgated in October 2018. H.R. 1425 - State Health Care Premium Reduction Act: Issues regarding state reinsurance program and providing financial assistance to reduce out-of-pocket costs. H.R. 820 - Public Health Service Act: Issues regarding National Institutes of Health support to collect the medical specimens and information of children with selected cancers that have the least effective treatments. H.R. 2069 - The SPIKE Act, H.R. 2113 - STAR Act, H.R. 2115 - Public Disclosure of Drug Discounts Act, H.R. 2296 - FAIR Drug Pricing Act, H.R. 2376 - Prescription Pricing for the People Act, H.R, 2757 - Creating Lower Cost Alternatives for Your Prescription Drugs Act, S. 657 - Drug Price Transparency (DPT) Act: Issues relating to drug and price transparency. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Regarding all provisions. S. 80, S. 172 - Issues regarding repeal and delay of the health insurer fee. Issues pertaining to surprise billing, including benchmark payments and arbitration models.

H.R. 1781 - Payment Commission Data Act of 2019: Issues regarding providing the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to drug pricing and rebate data. H.R. 938 - Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019: Issues regarding discouraging parking of 180-day exclusivity by a first generic applicant that is blocking the approval of other generics. H.R. 1520 - Purple Book Continuity Act of 2019: Issues regarding codifying publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book; Publication and regular updating of the Purple Book electronically on the FDAs website. H.R. 1503 - Orange Book Transparency Act of 2019: Issues regarding ensuring that the Orange Book is accurate and up-to-date, by requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019: Issues regarding brand-name and generic drug manufacturers entering into agreements in which the brand-name drug manufacturer pays the generic manufacturer to keep a generic equivalent off the market. H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 1385 - State Allowance for a Variety of Exchanges (SAVE) Act: Issues regarding federal funds to establish state-based Marketplaces. H.R. 1386 - Expand Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act: Issues regarding funding for Federally-Facilitated Marketplace navigator program; requirements for navigator entities in each state; Health and Human Services ensuring that navigator grants are awarded to entities with demonstrated capacity to carry out the duties specified in the Affordable Care Act. H.R. 987 - Marketing and Outreach Restoration to Empower (MORE) Health Education Act of 2019: Issues related to restoring outreach and enrollment funding to assist consumers in signing up for health care. H.R. 1010 - Issues regarding Short-Term, Limited Duration Insurance. H.R. 986 - Protecting Americans with Preexisting Conditions Act of 2019: Issues regarding rescinding Section 1332 guidance of the ACA promulgated in October 2018. H.R. 1425 - State Health Care Premium Reduction Act: Issues regarding state reinsurance program and providing financial assistance to reduce out-of-pocket costs. H.R. 820 - Public Health Service Act: Issues regarding National Institutes of Health support to collect the medical specimens and information of children with selected cancers that have the least effective treatments. H.R. 2069 - The SPIKE Act, H.R. 2113 - STAR Act, H.R. 2115 - Public Disclosure of Drug Discounts Act, H.R. 2296 - FAIR Drug Pricing Act, H.R. 2376 - Prescription Pricing for the People Act, H.R, 2757 - Creating Lower Cost Alternatives for Your Prescription Drugs Act, S. 657 - Drug Price Transparency (DPT) Act: Issues relating to drug and price transparency. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Regarding all provisions. S. 80, S. 172 - Issues regarding repeal and delay of the health insurer fee. Issues pertaining to surprise billing, including benchmark payments and arbitration models.

H.R. 1781 - Payment Commission Data Act of 2019: Issues regarding providing the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to drug pricing and rebate data. H.R. 938 - Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019: Issues regarding discouraging parking of 180-day exclusivity by a first generic applicant that is blocking the approval of other generics. H.R. 1520 - Purple Book Continuity Act of 2019: Issues regarding codifying publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book; Publication and regular updating of the Purple Book electronically on the FDAs website. H.R. 1503 - Orange Book Transparency Act of 2019: Issues regarding ensuring that the Orange Book is accurate and up-to-date, by requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019: Issues regarding brand-name and generic drug manufacturers entering into agreements in which the brand-name drug manufacturer pays the generic manufacturer to keep a generic equivalent off the market. H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 1385 - State Allowance for a Variety of Exchanges (SAVE) Act: Issues regarding federal funds to establish state-based Marketplaces. H.R. 1386 - Expand Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act: Issues regarding funding for Federally-Facilitated Marketplace navigator program; requirements for navigator entities in each state; Health and Human Services ensuring that navigator grants are awarded to entities with demonstrated capacity to carry out the duties specified in the Affordable Care Act. H.R. 987 - Marketing and Outreach Restoration to Empower (MORE) Health Education Act of 2019: Issues related to restoring outreach and enrollment funding to assist consumers in signing up for health care. H.R. 1010 - Issues regarding Short-Term, Limited Duration Insurance. H.R. 986 - Protecting Americans with Preexisting Conditions Act of 2019: Issues regarding rescinding Section 1332 guidance of the ACA promulgated in October 2018. H.R. 1425 - State Health Care Premium Reduction Act: Issues regarding state reinsurance program and providing financial assistance to reduce out-of-pocket costs. H.R. 820 - Public Health Service Act: Issues regarding National Institutes of Health support to collect the medical specimens and information of children with selected cancers that have the least effective treatments. 657 - Drug Price Transparency (DPT) Act: Issues relating to drug and price transparency. S. 80, S. 172 - Issues regarding repeal and delay of the health insurer fee. Issues regarding surprise billing, including benchmark payments and arbitration models.

H.R. 1781 - Payment Commission Data Act of 2019: Issues regarding providing the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to drug pricing and rebate data. H.R. 938 - Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019: Issues regarding discouraging parking of 180-day exclusivity by a first generic applicant that is blocking the approval of other generics. H.R. 1520 - Purple Book Continuity Act of 2019: Issues regarding codifying publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book; Publication and regular updating of the Purple Book electronically on the FDAs website. H.R. 1503 - Orange Book Transparency Act of 2019: Issues regarding ensuring that the Orange Book is accurate and up-to-date, by requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019: Issues regarding brand-name and generic drug manufacturers entering into agreements in which the brand-name drug manufacturer pays the generic manufacturer to keep a generic equivalent off the market. H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 1385 - State Allowance for a Variety of Exchanges (SAVE) Act: Issues regarding federal funds to establish state-based Marketplaces. H.R. 1386 - Expand Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act: Issues regarding funding for Federally-Facilitated Marketplace navigator program; requirements for navigator entities in each state; Health and Human Services ensuring that navigator grants are awarded to entities with demonstrated capacity to carry out the duties specified in the Affordable Care Act. H.R. 987 - Marketing and Outreach Restoration to Empower (MORE) Health Education Act of 2019: Issues related to restoring outreach and enrollment funding to assist consumers in signing up for health care. H.R. 1010 - Issues regarding Short-Term, Limited Duration Insurance. H.R. 986 - Protecting Americans with Preexisting Conditions Act of 2019: Issues regarding rescinding Section 1332 guidance of the ACA promulgated in October 2018. H.R. 1425 - State Health Care Premium Reduction Act: Issues regarding state reinsurance program and providing financial assistance to reduce out-of-pocket costs. H.R. 820 - Public Health Service Act: Issues regarding National Institutes of Health support to collect the medical specimens and information of children with selected cancers that have the least effective treatments. 657 - Drug Price Transparency (DPT) Act: Issues relating to drug and price transparency. S. 80, S. 172 - Issues regarding repeal and delay of the health insurer fee. Issues regarding surprise billing, including benchmark payments and arbitration models.

H.R. 1781 - Payment Commission Data Act of 2019: Issues regarding providing the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to drug pricing and rebate data. H.R. 938 - Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019: Issues regarding discouraging parking of 180-day exclusivity by a first generic applicant that is blocking the approval of other generics. H.R. 1520 - Purple Book Continuity Act of 2019: Issues regarding codifying publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book; Publication and regular updating of the Purple Book electronically on the FDAs website. H.R. 1503 - Orange Book Transparency Act of 2019: Issues regarding ensuring that the Orange Book is accurate and up-to-date, by requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019: Issues regarding brand-name and generic drug manufacturers entering into agreements in which the brand-name drug manufacturer pays the generic manufacturer to keep a generic equivalent off the market. H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 1385 - State Allowance for a Variety of Exchanges (SAVE) Act: Issues regarding federal funds to establish state-based Marketplaces. H.R. 1386 - Expand Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act: Issues regarding funding for Federally-Facilitated Marketplace navigator program; requirements for navigator entities in each state; Health and Human Services ensuring that navigator grants are awarded to entities with demonstrated capacity to carry out the duties specified in the Affordable Care Act. H.R. 987 - Marketing and Outreach Restoration to Empower (MORE) Health Education Act of 2019: Issues related to restoring outreach and enrollment funding to assist consumers in signing up for health care. H.R. 1010 - Issues regarding Short-Term, Limited Duration Insurance. H.R. 986 - Protecting Americans with Preexisting Conditions Act of 2019: Issues regarding rescinding Section 1332 guidance of the ACA promulgated in October 2018. H.R. 1425 - State Health Care Premium Reduction Act: Issues regarding state reinsurance program and providing financial assistance to reduce out-of-pocket costs. H.R. 820 - Public Health Service Act: Issues regarding National Institutes of Health support to collect the medical specimens and information of children with selected cancers that have the least effective treatments. H.R. 2069 - The SPIKE Act, H.R. 2113 - STAR Act, H.R. 2115 - Public Disclosure of Drug Discounts Act, H.R. 2296 - FAIR Drug Pricing Act, H.R. 2376 - Prescription Pricing for the People Act, H.R, 2757 - Creating Lower Cost Alternatives for Your Prescription Drugs Act, S. 657 - Drug Price Transparency (DPT) Act: Issues relating to drug and price transparency. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Regarding all provisions. S. 80, S. 172 - Issues regarding repeal and delay of the health insurer fee. Issues pertaining to surprise billing, including benchmark payments and arbitration models.

H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Issues related to ACA reinsurance/stabilization; rural health access; health equity; Medicare Advantage; Medicaid Rebates; Medicaid Expansion; Rate Notice and Call Letter; Medicare Part D; NBPP, Part D Donut Hole; Prescription Rebates; Privacy; Universal Coverage. H.R. 3439 - Protecting Access To Information for Effective and Necessary Treatment Act, PATIENT Act: Regarding all provisions. H.R. 861 - End Surprise Billing Act, HR 3630 - No Surprises Act, H.R. 3502 - Protecting People from Surprise Medical Bills Act; Issues relating to surprise billing, including benchmark payments, arbitration models, and out of network billing. H.R. 1897, S. 916 - MOMMAs Act, H.R. 2602, S. 1343 - MOMMIES Act, H.R. 1551 - Quality Care for Moms and Babies Act, H.R. 2902 - Maternal Care Act: Issues related to options for states to extend coverage for pregnant women eligible for Medicaid via the pregnancy pathway to 365 days, Minority Maternity Care, Social Determinants of Health. S. 657 - Drug Price Transparency (DPT) Act, S. 2543 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug and price transparency. H.R. 3- Lower Drug Costs Now Act of 2019, S. 102 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug costs. Centers for Medicare and Medicaid Services 84 FR 39398 - Hospital Outpatient Prospective Payment System (OPPS); EO 13877 / 84 FR 30849 - Improving Price and Quality Transparency in American Healthcare To Put Patients First; Centers for Medicare and Medicaid Services Proposed Rule 84 FR 7610 - Interoperability and Patient Access; Office of National Coordinator for Health Information Technology Proposed Rule 84 FR 7424 - Interoperability, Information Blocking, and the ONC Health IT Certification Program; Issues relating to drug and price transparency.

H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Issues related to ACA reinsurance/stabilization; rural health access; health equity; Medicare Advantage; Medicaid Rebates; Medicaid Expansion; Rate Notice and Call Letter; Medicare Part D; NBPP, Part D Donut Hole; Prescription Rebates; Privacy; Universal Coverage. H.R. 3439 - Protecting Access To Information for Effective and Necessary Treatment Act, PATIENT Act: Regarding all provisions. H.R. 861 - End Surprise Billing Act, HR 3630 - No Surprises Act, H.R. 3502 - Protecting People from Surprise Medical Bills Act; Issues relating to surprise billing, including benchmark payments, arbitration models, and out of network billing. H.R. 1897, S. 916 - MOMMAs Act, H.R. 2602, S. 1343 - MOMMIES Act, H.R. 1551 - Quality Care for Moms and Babies Act, H.R. 2902 - Maternal Care Act: Issues related to options for states to extend coverage for pregnant women eligible for Medicaid via the pregnancy pathway to 365 days, Minority Maternity Care, Social Determinants of Health. S. 657 - Drug Price Transparency (DPT) Act, S. 2543 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug and price transparency. H.R. 3- Lower Drug Costs Now Act of 2019, S. 102 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug costs. Centers for Medicare and Medicaid Services 84 FR 39398 - Hospital Outpatient Prospective Payment System (OPPS); EO 13877 / 84 FR 30849 - Improving Price and Quality Transparency in American Healthcare To Put Patients First; Centers for Medicare and Medicaid Services Proposed Rule 84 FR 7610 - Interoperability and Patient Access; Office of National Coordinator for Health Information Technology Proposed Rule 84 FR 7424 - Interoperability, Information Blocking, and the ONC Health IT Certification Program; Issues relating to drug and price transparency.

H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Issues related to ACA reinsurance/stabilization; rural health access; health equity; Medicare Advantage; Medicaid Rebates; Medicaid Expansion; Rate Notice and Call Letter; Medicare Part D; NBPP, Part D Donut Hole; Prescription Rebates; Privacy; Universal Coverage. H.R. 3439 - Protecting Access To Information for Effective and Necessary Treatment Act, PATIENT Act: Regarding all provisions. H.R. 861 - End Surprise Billing Act, HR 3630 - No Surprises Act, H.R. 3502 - Protecting People from Surprise Medical Bills Act; Issues relating to surprise billing, including benchmark payments, arbitration models, and out of network billing. H.R. 1897, S. 916 - MOMMAs Act, H.R. 2602, S. 1343 - MOMMIES Act, H.R. 1551 - Quality Care for Moms and Babies Act, H.R. 2902 - Maternal Care Act: Issues related to options for states to extend coverage for pregnant women eligible for Medicaid via the pregnancy pathway to 365 days, Minority Maternity Care, Social Determinants of Health. S. 657 - Drug Price Transparency (DPT) Act, S. 2543 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug and price transparency. H.R. 3- Lower Drug Costs Now Act of 2019, S. 102 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug costs. Centers for Medicare and Medicaid Services 84 FR 39398 - Hospital Outpatient Prospective Payment System (OPPS); EO 13877 / 84 FR 30849 - Improving Price and Quality Transparency in American Healthcare To Put Patients First; Centers for Medicare and Medicaid Services Proposed Rule 84 FR 7610 - Interoperability and Patient Access; Office of National Coordinator for Health Information Technology Proposed Rule 84 FR 7424 - Interoperability, Information Blocking, and the ONC Health IT Certification Program; Issues relating to drug and price transparency.

H.R. 1781 - Payment Commission Data Act of 2019: Issues regarding providing the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to drug pricing and rebate data. H.R. 938 - Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019: Issues regarding discouraging parking of 180-day exclusivity by a first generic applicant that is blocking the approval of other generics. H.R. 1520 - Purple Book Continuity Act of 2019: Issues regarding codifying publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book; Publication and regular updating of the Purple Book electronically on the FDAs website. H.R. 1503 - Orange Book Transparency Act of 2019: Issues regarding ensuring that the Orange Book is accurate and up-to-date, by requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019: Issues regarding brand-name and generic drug manufacturers entering into agreements in which the brand-name drug manufacturer pays the generic manufacturer to keep a generic equivalent off the market. H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 1385 - State Allowance for a Variety of Exchanges (SAVE) Act: Issues regarding federal funds to establish state-based Marketplaces. H.R. 1386 - Expand Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act: Issues regarding funding for Federally-Facilitated Marketplace navigator program; requirements for navigator entities in each state; Health and Human Services ensuring that navigator grants are awarded to entities with demonstrated capacity to carry out the duties specified in the Affordable Care Act. H.R. 987 - Marketing and Outreach Restoration to Empower (MORE) Health Education Act of 2019: Issues related to restoring outreach and enrollment funding to assist consumers in signing up for health care. H.R. 1010 - Issues regarding Short-Term, Limited Duration Insurance. H.R. 986 - Protecting Americans with Preexisting Conditions Act of 2019: Issues regarding rescinding Section 1332 guidance of the ACA promulgated in October 2018. H.R. 1425 - State Health Care Premium Reduction Act: Issues regarding state reinsurance program and providing financial assistance to reduce out-of-pocket costs. H.R. 820 - Public Health Service Act: Issues regarding National Institutes of Health support to collect the medical specimens and information of children with selected cancers that have the least effective treatments. H.R. 2069 - The SPIKE Act, H.R. 2113 - STAR Act, H.R. 2115 - Public Disclosure of Drug Discounts Act, H.R. 2296 - FAIR Drug Pricing Act, H.R. 2376 - Prescription Pricing for the People Act, H.R, 2757 - Creating Lower Cost Alternatives for Your Prescription Drugs Act, S. 657 - Drug Price Transparency (DPT) Act: Issues relating to drug and price transparency. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Regarding all provisions. S. 80, S. 172 - Issues regarding repeal and delay of the health insurer fee. Issues pertaining to surprise billing, including benchmark payments and arbitration models.

H.R. 1781 - Payment Commission Data Act of 2019: Issues regarding providing the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to drug pricing and rebate data. H.R. 938 - Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019: Issues regarding discouraging parking of 180-day exclusivity by a first generic applicant that is blocking the approval of other generics. H.R. 1520 - Purple Book Continuity Act of 2019: Issues regarding codifying publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book; Publication and regular updating of the Purple Book electronically on the FDAs website. H.R. 1503 - Orange Book Transparency Act of 2019: Issues regarding ensuring that the Orange Book is accurate and up-to-date, by requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019: Issues regarding brand-name and generic drug manufacturers entering into agreements in which the brand-name drug manufacturer pays the generic manufacturer to keep a generic equivalent off the market. H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 1385 - State Allowance for a Variety of Exchanges (SAVE) Act: Issues regarding federal funds to establish state-based Marketplaces. H.R. 1386 - Expand Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act: Issues regarding funding for Federally-Facilitated Marketplace navigator program; requirements for navigator entities in each state; Health and Human Services ensuring that navigator grants are awarded to entities with demonstrated capacity to carry out the duties specified in the Affordable Care Act. H.R. 987 - Marketing and Outreach Restoration to Empower (MORE) Health Education Act of 2019: Issues related to restoring outreach and enrollment funding to assist consumers in signing up for health care. H.R. 1010 - Issues regarding Short-Term, Limited Duration Insurance. H.R. 986 - Protecting Americans with Preexisting Conditions Act of 2019: Issues regarding rescinding Section 1332 guidance of the ACA promulgated in October 2018. H.R. 1425 - State Health Care Premium Reduction Act: Issues regarding state reinsurance program and providing financial assistance to reduce out-of-pocket costs. H.R. 820 - Public Health Service Act: Issues regarding National Institutes of Health support to collect the medical specimens and information of children with selected cancers that have the least effective treatments. H.R. 2069 - The SPIKE Act, H.R. 2113 - STAR Act, H.R. 2115 - Public Disclosure of Drug Discounts Act, H.R. 2296 - FAIR Drug Pricing Act, H.R. 2376 - Prescription Pricing for the People Act, H.R, 2757 - Creating Lower Cost Alternatives for Your Prescription Drugs Act, S. 657 - Drug Price Transparency (DPT) Act: Issues relating to drug and price transparency. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Regarding all provisions. S. 80, S. 172 - Issues regarding repeal and delay of the health insurer fee. Issues pertaining to surprise billing, including benchmark payments and arbitration models.

H.R. 1781 - Payment Commission Data Act of 2019: Issues regarding providing the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to drug pricing and rebate data. H.R. 938 - Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019: Issues regarding discouraging parking of 180-day exclusivity by a first generic applicant that is blocking the approval of other generics. H.R. 1520 - Purple Book Continuity Act of 2019: Issues regarding codifying publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book; Publication and regular updating of the Purple Book electronically on the FDAs website. H.R. 1503 - Orange Book Transparency Act of 2019: Issues regarding ensuring that the Orange Book is accurate and up-to-date, by requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019: Issues regarding brand-name and generic drug manufacturers entering into agreements in which the brand-name drug manufacturer pays the generic manufacturer to keep a generic equivalent off the market. H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 1385 - State Allowance for a Variety of Exchanges (SAVE) Act: Issues regarding federal funds to establish state-based Marketplaces. H.R. 1386 - Expand Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act: Issues regarding funding for Federally-Facilitated Marketplace navigator program; requirements for navigator entities in each state; Health and Human Services ensuring that navigator grants are awarded to entities with demonstrated capacity to carry out the duties specified in the Affordable Care Act. H.R. 987 - Marketing and Outreach Restoration to Empower (MORE) Health Education Act of 2019: Issues related to restoring outreach and enrollment funding to assist consumers in signing up for health care. H.R. 1010 - Issues regarding Short-Term, Limited Duration Insurance. H.R. 986 - Protecting Americans with Preexisting Conditions Act of 2019: Issues regarding rescinding Section 1332 guidance of the ACA promulgated in October 2018. H.R. 1425 - State Health Care Premium Reduction Act: Issues regarding state reinsurance program and providing financial assistance to reduce out-of-pocket costs. H.R. 820 - Public Health Service Act: Issues regarding National Institutes of Health support to collect the medical specimens and information of children with selected cancers that have the least effective treatments. H.R. 2069 - The SPIKE Act, H.R. 2113 - STAR Act, H.R. 2115 - Public Disclosure of Drug Discounts Act, H.R. 2296 - FAIR Drug Pricing Act, H.R. 2376 - Prescription Pricing for the People Act, H.R, 2757 - Creating Lower Cost Alternatives for Your Prescription Drugs Act, S. 657 - Drug Price Transparency (DPT) Act: Issues relating to drug and price transparency. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Regarding all provisions. S. 80, S. 172 - Issues regarding repeal and delay of the health insurer fee. Issues pertaining to surprise billing, including benchmark payments and arbitration models.

H.R. 1781 - Payment Commission Data Act of 2019: Issues regarding providing the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to drug pricing and rebate data. H.R. 938 - Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019: Issues regarding discouraging parking of 180-day exclusivity by a first generic applicant that is blocking the approval of other generics. H.R. 1520 - Purple Book Continuity Act of 2019: Issues regarding codifying publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book; Publication and regular updating of the Purple Book electronically on the FDAs website. H.R. 1503 - Orange Book Transparency Act of 2019: Issues regarding ensuring that the Orange Book is accurate and up-to-date, by requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019: Issues regarding brand-name and generic drug manufacturers entering into agreements in which the brand-name drug manufacturer pays the generic manufacturer to keep a generic equivalent off the market. H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 1385 - State Allowance for a Variety of Exchanges (SAVE) Act: Issues regarding federal funds to establish state-based Marketplaces. H.R. 1386 - Expand Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act: Issues regarding funding for Federally-Facilitated Marketplace navigator program; requirements for navigator entities in each state; Health and Human Services ensuring that navigator grants are awarded to entities with demonstrated capacity to carry out the duties specified in the Affordable Care Act. H.R. 987 - Marketing and Outreach Restoration to Empower (MORE) Health Education Act of 2019: Issues related to restoring outreach and enrollment funding to assist consumers in signing up for health care. H.R. 1010 - Issues regarding Short-Term, Limited Duration Insurance. H.R. 986 - Protecting Americans with Preexisting Conditions Act of 2019: Issues regarding rescinding Section 1332 guidance of the ACA promulgated in October 2018. H.R. 1425 - State Health Care Premium Reduction Act: Issues regarding state reinsurance program and providing financial assistance to reduce out-of-pocket costs. H.R. 820 - Public Health Service Act: Issues regarding National Institutes of Health support to collect the medical specimens and information of children with selected cancers that have the least effective treatments. H.R. 2069 - The SPIKE Act, H.R. 2113 - STAR Act, H.R. 2115 - Public Disclosure of Drug Discounts Act, H.R. 2296 - FAIR Drug Pricing Act, H.R. 2376 - Prescription Pricing for the People Act, H.R, 2757 - Creating Lower Cost Alternatives for Your Prescription Drugs Act, S. 657 - Drug Price Transparency (DPT) Act: Issues relating to drug and price transparency. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Regarding all provisions. S. 80, S. 172 - Issues regarding repeal and delay of the health insurer fee. Issues pertaining to surprise billing, including benchmark payments and arbitration models.

H.R. 1781 - Payment Commission Data Act of 2019: Issues regarding providing the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to drug pricing and rebate data. H.R. 938 - Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019: Issues regarding discouraging parking of 180-day exclusivity by a first generic applicant that is blocking the approval of other generics. H.R. 1520 - Purple Book Continuity Act of 2019: Issues regarding codifying publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book; Publication and regular updating of the Purple Book electronically on the FDAs website. H.R. 1503 - Orange Book Transparency Act of 2019: Issues regarding ensuring that the Orange Book is accurate and up-to-date, by requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019: Issues regarding brand-name and generic drug manufacturers entering into agreements in which the brand-name drug manufacturer pays the generic manufacturer to keep a generic equivalent off the market. H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 1385 - State Allowance for a Variety of Exchanges (SAVE) Act: Issues regarding federal funds to establish state-based Marketplaces. H.R. 1386 - Expand Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act: Issues regarding funding for Federally-Facilitated Marketplace navigator program; requirements for navigator entities in each state; Health and Human Services ensuring that navigator grants are awarded to entities with demonstrated capacity to carry out the duties specified in the Affordable Care Act. H.R. 987 - Marketing and Outreach Restoration to Empower (MORE) Health Education Act of 2019: Issues related to restoring outreach and enrollment funding to assist consumers in signing up for health care. H.R. 1010 - Issues regarding Short-Term, Limited Duration Insurance. H.R. 986 - Protecting Americans with Preexisting Conditions Act of 2019: Issues regarding rescinding Section 1332 guidance of the ACA promulgated in October 2018. H.R. 1425 - State Health Care Premium Reduction Act: Issues regarding state reinsurance program and providing financial assistance to reduce out-of-pocket costs. H.R. 820 - Public Health Service Act: Issues regarding National Institutes of Health support to collect the medical specimens and information of children with selected cancers that have the least effective treatments. H.R. 2069 - The SPIKE Act, H.R. 2113 - STAR Act, H.R. 2115 - Public Disclosure of Drug Discounts Act, H.R. 2296 - FAIR Drug Pricing Act, H.R. 2376 - Prescription Pricing for the People Act, H.R, 2757 - Creating Lower Cost Alternatives for Your Prescription Drugs Act, S. 657 - Drug Price Transparency (DPT) Act: Issues relating to drug and price transparency. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Regarding all provisions. S. 80, S. 172 - Issues regarding repeal and delay of the health insurer fee. Issues pertaining to surprise billing, including benchmark payments and arbitration models.

H.R. 1781 - Payment Commission Data Act of 2019: Issues regarding providing the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to drug pricing and rebate data. H.R. 938 - Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019: Issues regarding discouraging parking of 180-day exclusivity by a first generic applicant that is blocking the approval of other generics. H.R. 1520 - Purple Book Continuity Act of 2019: Issues regarding codifying publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book; Publication and regular updating of the Purple Book electronically on the FDAs website. H.R. 1503 - Orange Book Transparency Act of 2019: Issues regarding ensuring that the Orange Book is accurate and up-to-date, by requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019: Issues regarding brand-name and generic drug manufacturers entering into agreements in which the brand-name drug manufacturer pays the generic manufacturer to keep a generic equivalent off the market. H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 1385 - State Allowance for a Variety of Exchanges (SAVE) Act: Issues regarding federal funds to establish state-based Marketplaces. H.R. 1386 - Expand Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act: Issues regarding funding for Federally-Facilitated Marketplace navigator program; requirements for navigator entities in each state; Health and Human Services ensuring that navigator grants are awarded to entities with demonstrated capacity to carry out the duties specified in the Affordable Care Act. H.R. 987 - Marketing and Outreach Restoration to Empower (MORE) Health Education Act of 2019: Issues related to restoring outreach and enrollment funding to assist consumers in signing up for health care. H.R. 1010 - Issues regarding Short-Term, Limited Duration Insurance. H.R. 986 - Protecting Americans with Preexisting Conditions Act of 2019: Issues regarding rescinding Section 1332 guidance of the ACA promulgated in October 2018. H.R. 1425 - State Health Care Premium Reduction Act: Issues regarding state reinsurance program and providing financial assistance to reduce out-of-pocket costs. H.R. 820 - Public Health Service Act: Issues regarding National Institutes of Health support to collect the medical specimens and information of children with selected cancers that have the least effective treatments. H.R. 2069 - The SPIKE Act, H.R. 2113 - STAR Act, H.R. 2115 - Public Disclosure of Drug Discounts Act, H.R. 2296 - FAIR Drug Pricing Act, H.R. 2376 - Prescription Pricing for the People Act, H.R, 2757 - Creating Lower Cost Alternatives for Your Prescription Drugs Act, S. 657 - Drug Price Transparency (DPT) Act: Issues relating to drug and price transparency. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Regarding all provisions. S. 80, S. 172 - Issues regarding repeal and delay of the health insurer fee. Issues pertaining to surprise billing, including benchmark payments and arbitration models.

H.R. 1781 - Payment Commission Data Act of 2019: Issues regarding providing the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to drug pricing and rebate data. H.R. 938 - Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019: Issues regarding discouraging parking of 180-day exclusivity by a first generic applicant that is blocking the approval of other generics. H.R. 1520 - Purple Book Continuity Act of 2019: Issues regarding codifying publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book; Publication and regular updating of the Purple Book electronically on the FDAs website. H.R. 1503 - Orange Book Transparency Act of 2019: Issues regarding ensuring that the Orange Book is accurate and up-to-date, by requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019: Issues regarding brand-name and generic drug manufacturers entering into agreements in which the brand-name drug manufacturer pays the generic manufacturer to keep a generic equivalent off the market. H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 1385 - State Allowance for a Variety of Exchanges (SAVE) Act: Issues regarding federal funds to establish state-based Marketplaces. H.R. 1386 - Expand Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act: Issues regarding funding for Federally-Facilitated Marketplace navigator program; requirements for navigator entities in each state; Health and Human Services ensuring that navigator grants are awarded to entities with demonstrated capacity to carry out the duties specified in the Affordable Care Act. H.R. 987 - Marketing and Outreach Restoration to Empower (MORE) Health Education Act of 2019: Issues related to restoring outreach and enrollment funding to assist consumers in signing up for health care. H.R. 1010 - Issues regarding Short-Term, Limited Duration Insurance. H.R. 986 - Protecting Americans with Preexisting Conditions Act of 2019: Issues regarding rescinding Section 1332 guidance of the ACA promulgated in October 2018. H.R. 1425 - State Health Care Premium Reduction Act: Issues regarding state reinsurance program and providing financial assistance to reduce out-of-pocket costs. H.R. 820 - Public Health Service Act: Issues regarding National Institutes of Health support to collect the medical specimens and information of children with selected cancers that have the least effective treatments. H.R. 2069 - The SPIKE Act, H.R. 2113 - STAR Act, H.R. 2115 - Public Disclosure of Drug Discounts Act, H.R. 2296 - FAIR Drug Pricing Act, H.R. 2376 - Prescription Pricing for the People Act, H.R, 2757 - Creating Lower Cost Alternatives for Your Prescription Drugs Act, S. 657 - Drug Price Transparency (DPT) Act: Issues relating to drug and price transparency. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Regarding all provisions. S. 80, S. 172 - Issues regarding repeal and delay of the health insurer fee. Issues pertaining to surprise billing, including benchmark payments and arbitration models.

H.R. 1781 - Payment Commission Data Act of 2019: Issues regarding providing the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to drug pricing and rebate data. H.R. 938 - Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019: Issues regarding discouraging parking of 180-day exclusivity by a first generic applicant that is blocking the approval of other generics. H.R. 1520 - Purple Book Continuity Act of 2019: Issues regarding codifying publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book; Publication and regular updating of the Purple Book electronically on the FDAs website. H.R. 1503 - Orange Book Transparency Act of 2019: Issues regarding ensuring that the Orange Book is accurate and up-to-date, by requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019: Issues regarding brand-name and generic drug manufacturers entering into agreements in which the brand-name drug manufacturer pays the generic manufacturer to keep a generic equivalent off the market. H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 1385 - State Allowance for a Variety of Exchanges (SAVE) Act: Issues regarding federal funds to establish state-based Marketplaces. H.R. 1386 - Expand Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act: Issues regarding funding for Federally-Facilitated Marketplace navigator program; requirements for navigator entities in each state; Health and Human Services ensuring that navigator grants are awarded to entities with demonstrated capacity to carry out the duties specified in the Affordable Care Act. H.R. 987 - Marketing and Outreach Restoration to Empower (MORE) Health Education Act of 2019: Issues related to restoring outreach and enrollment funding to assist consumers in signing up for health care. H.R. 1010 - Issues regarding Short-Term, Limited Duration Insurance. H.R. 986 - Protecting Americans with Preexisting Conditions Act of 2019: Issues regarding rescinding Section 1332 guidance of the ACA promulgated in October 2018. H.R. 1425 - State Health Care Premium Reduction Act: Issues regarding state reinsurance program and providing financial assistance to reduce out-of-pocket costs. H.R. 820 - Public Health Service Act: Issues regarding National Institutes of Health support to collect the medical specimens and information of children with selected cancers that have the least effective treatments. H.R. 2069 - The SPIKE Act, H.R. 2113 - STAR Act, H.R. 2115 - Public Disclosure of Drug Discounts Act, H.R. 2296 - FAIR Drug Pricing Act, H.R. 2376 - Prescription Pricing for the People Act, H.R, 2757 - Creating Lower Cost Alternatives for Your Prescription Drugs Act, S. 657 - Drug Price Transparency (DPT) Act: Issues relating to drug and price transparency. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Regarding all provisions. S. 80, S. 172 - Issues regarding repeal and delay of the health insurer fee. Issues pertaining to surprise billing, including benchmark payments and arbitration models.

H.R. 1781 - Payment Commission Data Act of 2019: Issues regarding providing the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to drug pricing and rebate data. H.R. 938 - Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019: Issues regarding discouraging parking of 180-day exclusivity by a first generic applicant that is blocking the approval of other generics. H.R. 1520 - Purple Book Continuity Act of 2019: Issues regarding codifying publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book; Publication and regular updating of the Purple Book electronically on the FDAs website. H.R. 1503 - Orange Book Transparency Act of 2019: Issues regarding ensuring that the Orange Book is accurate and up-to-date, by requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019: Issues regarding brand-name and generic drug manufacturers entering into agreements in which the brand-name drug manufacturer pays the generic manufacturer to keep a generic equivalent off the market. H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 1385 - State Allowance for a Variety of Exchanges (SAVE) Act: Issues regarding federal funds to establish state-based Marketplaces. H.R. 1386 - Expand Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act: Issues regarding funding for Federally-Facilitated Marketplace navigator program; requirements for navigator entities in each state; Health and Human Services ensuring that navigator grants are awarded to entities with demonstrated capacity to carry out the duties specified in the Affordable Care Act. H.R. 987 - Marketing and Outreach Restoration to Empower (MORE) Health Education Act of 2019: Issues related to restoring outreach and enrollment funding to assist consumers in signing up for health care. H.R. 1010 - Issues regarding Short-Term, Limited Duration Insurance. H.R. 986 - Protecting Americans with Preexisting Conditions Act of 2019: Issues regarding rescinding Section 1332 guidance of the ACA promulgated in October 2018. H.R. 1425 - State Health Care Premium Reduction Act: Issues regarding state reinsurance program and providing financial assistance to reduce out-of-pocket costs. H.R. 820 - Public Health Service Act: Issues regarding National Institutes of Health support to collect the medical specimens and information of children with selected cancers that have the least effective treatments. H.R. 2069 - The SPIKE Act, H.R. 2113 - STAR Act, H.R. 2115 - Public Disclosure of Drug Discounts Act, H.R. 2296 - FAIR Drug Pricing Act, H.R. 2376 - Prescription Pricing for the People Act, H.R, 2757 - Creating Lower Cost Alternatives for Your Prescription Drugs Act, S. 657 - Drug Price Transparency (DPT) Act: Issues relating to drug and price transparency. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Regarding all provisions. S. 80, S. 172 - Issues regarding repeal and delay of the health insurer fee. Issues pertaining to surprise billing, including benchmark payments and arbitration models.

H.R. 1781 - Payment Commission Data Act of 2019: Issues regarding providing the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to drug pricing and rebate data. H.R. 938 - Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019: Issues regarding discouraging parking of 180-day exclusivity by a first generic applicant that is blocking the approval of other generics. H.R. 1520 - Purple Book Continuity Act of 2019: Issues regarding codifying publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book; Publication and regular updating of the Purple Book electronically on the FDAs website. H.R. 1503 - Orange Book Transparency Act of 2019: Issues regarding ensuring that the Orange Book is accurate and up-to-date, by requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019: Issues regarding brand-name and generic drug manufacturers entering into agreements in which the brand-name drug manufacturer pays the generic manufacturer to keep a generic equivalent off the market. H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 1385 - State Allowance for a Variety of Exchanges (SAVE) Act: Issues regarding federal funds to establish state-based Marketplaces. H.R. 1386 - Expand Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act: Issues regarding funding for Federally-Facilitated Marketplace navigator program; requirements for navigator entities in each state; Health and Human Services ensuring that navigator grants are awarded to entities with demonstrated capacity to carry out the duties specified in the Affordable Care Act. H.R. 987 - Marketing and Outreach Restoration to Empower (MORE) Health Education Act of 2019: Issues related to restoring outreach and enrollment funding to assist consumers in signing up for health care. H.R. 1010 - Issues regarding Short-Term, Limited Duration Insurance. H.R. 986 - Protecting Americans with Preexisting Conditions Act of 2019: Issues regarding rescinding Section 1332 guidance of the ACA promulgated in October 2018. H.R. 1425 - State Health Care Premium Reduction Act: Issues regarding state reinsurance program and providing financial assistance to reduce out-of-pocket costs. H.R. 820 - Public Health Service Act: Issues regarding National Institutes of Health support to collect the medical specimens and information of children with selected cancers that have the least effective treatments. H.R. 2069 - The SPIKE Act, H.R. 2113 - STAR Act, H.R. 2115 - Public Disclosure of Drug Discounts Act, H.R. 2296 - FAIR Drug Pricing Act, H.R. 2376 - Prescription Pricing for the People Act, H.R, 2757 - Creating Lower Cost Alternatives for Your Prescription Drugs Act, S. 657 - Drug Price Transparency (DPT) Act: Issues relating to drug and price transparency. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Regarding all provisions. S. 80, S. 172 - Issues regarding repeal and delay of the health insurer fee. Issues pertaining to surprise billing, including benchmark payments and arbitration models.

H.R. 1781 - Payment Commission Data Act of 2019: Issues regarding providing the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to drug pricing and rebate data. H.R. 938 - Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019: Issues regarding discouraging parking of 180-day exclusivity by a first generic applicant that is blocking the approval of other generics. H.R. 1520 - Purple Book Continuity Act of 2019: Issues regarding codifying publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book; Publication and regular updating of the Purple Book electronically on the FDAs website. H.R. 1503 - Orange Book Transparency Act of 2019: Issues regarding ensuring that the Orange Book is accurate and up-to-date, by requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019: Issues regarding brand-name and generic drug manufacturers entering into agreements in which the brand-name drug manufacturer pays the generic manufacturer to keep a generic equivalent off the market. H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 1385 - State Allowance for a Variety of Exchanges (SAVE) Act: Issues regarding federal funds to establish state-based Marketplaces. H.R. 1386 - Expand Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act: Issues regarding funding for Federally-Facilitated Marketplace navigator program; requirements for navigator entities in each state; Health and Human Services ensuring that navigator grants are awarded to entities with demonstrated capacity to carry out the duties specified in the Affordable Care Act. H.R. 987 - Marketing and Outreach Restoration to Empower (MORE) Health Education Act of 2019: Issues related to restoring outreach and enrollment funding to assist consumers in signing up for health care. H.R. 1010 - Issues regarding Short-Term, Limited Duration Insurance. H.R. 986 - Protecting Americans with Preexisting Conditions Act of 2019: Issues regarding rescinding Section 1332 guidance of the ACA promulgated in October 2018. H.R. 1425 - State Health Care Premium Reduction Act: Issues regarding state reinsurance program and providing financial assistance to reduce out-of-pocket costs. H.R. 820 - Public Health Service Act: Issues regarding National Institutes of Health support to collect the medical specimens and information of children with selected cancers that have the least effective treatments. H.R. 2069 - The SPIKE Act, H.R. 2113 - STAR Act, H.R. 2115 - Public Disclosure of Drug Discounts Act, H.R. 2296 - FAIR Drug Pricing Act, H.R. 2376 - Prescription Pricing for the People Act, H.R, 2757 - Creating Lower Cost Alternatives for Your Prescription Drugs Act, S. 657 - Drug Price Transparency (DPT) Act: Issues relating to drug and price transparency. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Regarding all provisions. S. 80, S. 172 - Issues regarding repeal and delay of the health insurer fee. Issues pertaining to surprise billing, including benchmark payments and arbitration models.

H.R. 1781 - Payment Commission Data Act of 2019: Issues regarding providing the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to drug pricing and rebate data. H.R. 938 - Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019: Issues regarding discouraging parking of 180-day exclusivity by a first generic applicant that is blocking the approval of other generics. H.R. 1520 - Purple Book Continuity Act of 2019: Issues regarding codifying publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book; Publication and regular updating of the Purple Book electronically on the FDAs website. H.R. 1503 - Orange Book Transparency Act of 2019: Issues regarding ensuring that the Orange Book is accurate and up-to-date, by requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019: Issues regarding brand-name and generic drug manufacturers entering into agreements in which the brand-name drug manufacturer pays the generic manufacturer to keep a generic equivalent off the market. H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 1385 - State Allowance for a Variety of Exchanges (SAVE) Act: Issues regarding federal funds to establish state-based Marketplaces. H.R. 1386 - Expand Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act: Issues regarding funding for Federally-Facilitated Marketplace navigator program; requirements for navigator entities in each state; Health and Human Services ensuring that navigator grants are awarded to entities with demonstrated capacity to carry out the duties specified in the Affordable Care Act. H.R. 987 - Marketing and Outreach Restoration to Empower (MORE) Health Education Act of 2019: Issues related to restoring outreach and enrollment funding to assist consumers in signing up for health care. H.R. 1010 - Issues regarding Short-Term, Limited Duration Insurance. H.R. 986 - Protecting Americans with Preexisting Conditions Act of 2019: Issues regarding rescinding Section 1332 guidance of the ACA promulgated in October 2018. H.R. 1425 - State Health Care Premium Reduction Act: Issues regarding state reinsurance program and providing financial assistance to reduce out-of-pocket costs. H.R. 820 - Public Health Service Act: Issues regarding National Institutes of Health support to collect the medical specimens and information of children with selected cancers that have the least effective treatments. H.R. 2069 - The SPIKE Act, H.R. 2113 - STAR Act, H.R. 2115 - Public Disclosure of Drug Discounts Act, H.R. 2296 - FAIR Drug Pricing Act, H.R. 2376 - Prescription Pricing for the People Act, H.R, 2757 - Creating Lower Cost Alternatives for Your Prescription Drugs Act, S. 657 - Drug Price Transparency (DPT) Act: Issues relating to drug and price transparency. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Regarding all provisions. S. 80, S. 172 - Issues regarding repeal and delay of the health insurer fee. Issues pertaining to surprise billing, including benchmark payments and arbitration models.

H.R. 1781 - Payment Commission Data Act of 2019: Issues regarding providing the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to drug pricing and rebate data. H.R. 938 - Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019: Issues regarding discouraging parking of 180-day exclusivity by a first generic applicant that is blocking the approval of other generics. H.R. 1520 - Purple Book Continuity Act of 2019: Issues regarding codifying publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book; Publication and regular updating of the Purple Book electronically on the FDAs website. H.R. 1503 - Orange Book Transparency Act of 2019: Issues regarding ensuring that the Orange Book is accurate and up-to-date, by requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019: Issues regarding brand-name and generic drug manufacturers entering into agreements in which the brand-name drug manufacturer pays the generic manufacturer to keep a generic equivalent off the market. H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 1385 - State Allowance for a Variety of Exchanges (SAVE) Act: Issues regarding federal funds to establish state-based Marketplaces. H.R. 1386 - Expand Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act: Issues regarding funding for Federally-Facilitated Marketplace navigator program; requirements for navigator entities in each state; Health and Human Services ensuring that navigator grants are awarded to entities with demonstrated capacity to carry out the duties specified in the Affordable Care Act. H.R. 987 - Marketing and Outreach Restoration to Empower (MORE) Health Education Act of 2019: Issues related to restoring outreach and enrollment funding to assist consumers in signing up for health care. H.R. 1010 - Issues regarding Short-Term, Limited Duration Insurance. H.R. 986 - Protecting Americans with Preexisting Conditions Act of 2019: Issues regarding rescinding Section 1332 guidance of the ACA promulgated in October 2018. H.R. 1425 - State Health Care Premium Reduction Act: Issues regarding state reinsurance program and providing financial assistance to reduce out-of-pocket costs. H.R. 820 - Public Health Service Act: Issues regarding National Institutes of Health support to collect the medical specimens and information of children with selected cancers that have the least effective treatments. H.R. 2069 - The SPIKE Act, H.R. 2113 - STAR Act, H.R. 2115 - Public Disclosure of Drug Discounts Act, H.R. 2296 - FAIR Drug Pricing Act, H.R. 2376 - Prescription Pricing for the People Act, H.R, 2757 - Creating Lower Cost Alternatives for Your Prescription Drugs Act, S. 657 - Drug Price Transparency (DPT) Act: Issues relating to drug and price transparency. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Regarding all provisions. S. 80, S. 172 - Issues regarding repeal and delay of the health insurer fee. Issues pertaining to surprise billing, including benchmark payments and arbitration models.

H.R. 1781 - Payment Commission Data Act of 2019: Issues regarding providing the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to drug pricing and rebate data. H.R. 938 - Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019: Issues regarding discouraging parking of 180-day exclusivity by a first generic applicant that is blocking the approval of other generics. H.R. 1520 - Purple Book Continuity Act of 2019: Issues regarding codifying publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book; Publication and regular updating of the Purple Book electronically on the FDAs website. H.R. 1503 - Orange Book Transparency Act of 2019: Issues regarding ensuring that the Orange Book is accurate and up-to-date, by requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019: Issues regarding brand-name and generic drug manufacturers entering into agreements in which the brand-name drug manufacturer pays the generic manufacturer to keep a generic equivalent off the market. H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 1385 - State Allowance for a Variety of Exchanges (SAVE) Act: Issues regarding federal funds to establish state-based Marketplaces. H.R. 1386 - Expand Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act: Issues regarding funding for Federally-Facilitated Marketplace navigator program; requirements for navigator entities in each state; Health and Human Services ensuring that navigator grants are awarded to entities with demonstrated capacity to carry out the duties specified in the Affordable Care Act. H.R. 987 - Marketing and Outreach Restoration to Empower (MORE) Health Education Act of 2019: Issues related to restoring outreach and enrollment funding to assist consumers in signing up for health care. H.R. 1010 - Issues regarding Short-Term, Limited Duration Insurance. H.R. 986 - Protecting Americans with Preexisting Conditions Act of 2019: Issues regarding rescinding Section 1332 guidance of the ACA promulgated in October 2018. H.R. 1425 - State Health Care Premium Reduction Act: Issues regarding state reinsurance program and providing financial assistance to reduce out-of-pocket costs. H.R. 820 - Public Health Service Act: Issues regarding National Institutes of Health support to collect the medical specimens and information of children with selected cancers that have the least effective treatments. H.R. 2069 - The SPIKE Act, H.R. 2113 - STAR Act, H.R. 2115 - Public Disclosure of Drug Discounts Act, H.R. 2296 - FAIR Drug Pricing Act, H.R. 2376 - Prescription Pricing for the People Act, H.R, 2757 - Creating Lower Cost Alternatives for Your Prescription Drugs Act, S. 657 - Drug Price Transparency (DPT) Act: Issues relating to drug and price transparency. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Regarding all provisions. S. 80, S. 172 - Issues regarding repeal and delay of the health insurer fee. Issues pertaining to surprise billing, including benchmark payments and arbitration models.

H.R. 1781 - Payment Commission Data Act of 2019: Issues regarding providing the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to drug pricing and rebate data. H.R. 938 - Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019: Issues regarding discouraging parking of 180-day exclusivity by a first generic applicant that is blocking the approval of other generics. H.R. 1520 - Purple Book Continuity Act of 2019: Issues regarding codifying publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book; Publication and regular updating of the Purple Book electronically on the FDAs website. H.R. 1503 - Orange Book Transparency Act of 2019: Issues regarding ensuring that the Orange Book is accurate and up-to-date, by requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019: Issues regarding brand-name and generic drug manufacturers entering into agreements in which the brand-name drug manufacturer pays the generic manufacturer to keep a generic equivalent off the market. H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 1385 - State Allowance for a Variety of Exchanges (SAVE) Act: Issues regarding federal funds to establish state-based Marketplaces. H.R. 1386 - Expand Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act: Issues regarding funding for Federally-Facilitated Marketplace navigator program; requirements for navigator entities in each state; Health and Human Services ensuring that navigator grants are awarded to entities with demonstrated capacity to carry out the duties specified in the Affordable Care Act. H.R. 987 - Marketing and Outreach Restoration to Empower (MORE) Health Education Act of 2019: Issues related to restoring outreach and enrollment funding to assist consumers in signing up for health care. H.R. 1010 - Issues regarding Short-Term, Limited Duration Insurance. H.R. 986 - Protecting Americans with Preexisting Conditions Act of 2019: Issues regarding rescinding Section 1332 guidance of the ACA promulgated in October 2018. H.R. 1425 - State Health Care Premium Reduction Act: Issues regarding state reinsurance program and providing financial assistance to reduce out-of-pocket costs. H.R. 820 - Public Health Service Act: Issues regarding National Institutes of Health support to collect the medical specimens and information of children with selected cancers that have the least effective treatments. H.R. 2069 - The SPIKE Act, H.R. 2113 - STAR Act, H.R. 2115 - Public Disclosure of Drug Discounts Act, H.R. 2296 - FAIR Drug Pricing Act, H.R. 2376 - Prescription Pricing for the People Act, H.R, 2757 - Creating Lower Cost Alternatives for Your Prescription Drugs Act, S. 657 - Drug Price Transparency (DPT) Act: Issues relating to drug and price transparency. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Regarding all provisions. S. 80, S. 172 - Issues regarding repeal and delay of the health insurer fee. Issues pertaining to surprise billing, including benchmark payments and arbitration models.

H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Issues related to rural health access; health equity; Medicare Advantage; Medicaid Rebates; Medicaid Expansion; Rate Notice and Call Letter; Medicare Part D; NBPP, Part D Donut Hole; Privacy; Universal Coverage. H.R. 259, Medicaid Extenders Act of 2019, H.R. 4378, Continuing Appropriations Act of 2020: Issues related to Medicaid extension. HR 1398, S. 172 - Health Insurance Tax Relief Act of 2019, S. 80 - Jobs and Premium Protection Act; Issues related to repeal and delay the health insurer fee. Issues related to the Affordable Care Act reinsurance/stabilization. H.R. 861 - End Surprise Billing Act, HR 3630 - No Surprises Act, H.R. 3502 - Protecting People from Surprise Medical Bills Act; Issues relating to surprise billing, including benchmark payments, arbitration models, and out of network billing. S. 916 - MOMMAs Act, H.R. 2602, S. 1343 - MOMMIES Act, HR 4996 - Helping Medicaid Offer Maternity Services Act of 2019: Issues related to options for states to extend coverage for pregnant women eligible for Medicaid via the pregnancy pathway to 365 days, Minority Maternity Care, Social Determinants of Health. S. 657 - Drug Price Transparency (DPT) Act, S. 2543 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug and price transparency. H.R. 3- Lower Drug Costs Now Act of 2019, S. 102 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug costs and prescription rebates. Issues relating to drug and price transparency, including the Administrations rule on interoperability and Executive order on transparency.

H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Issues related to rural health access; health equity; Medicare Advantage; Medicaid Rebates; Medicaid Expansion; Rate Notice and Call Letter; Medicare Part D; NBPP, Part D Donut Hole; Privacy; Universal Coverage. H.R. 259, Medicaid Extenders Act of 2019, H.R. 4378, Continuing Appropriations Act of 2020: Issues related to Medicaid extension. HR 1398, S. 172 - Health Insurance Tax Relief Act of 2019, S. 80 - Jobs and Premium Protection Act; Issues related to repeal and delay the health insurer fee. Issues related to the Affordable Care Act reinsurance/stabilization. H.R. 861 - End Surprise Billing Act, HR 3630 - No Surprises Act, H.R. 3502 - Protecting People from Surprise Medical Bills Act; Issues relating to surprise billing, including benchmark payments, arbitration models, and out of network billing. S. 916 - MOMMAs Act, H.R. 2602, S. 1343 - MOMMIES Act, HR 4996 - Helping Medicaid Offer Maternity Services Act of 2019: Issues related to options for states to extend coverage for pregnant women eligible for Medicaid via the pregnancy pathway to 365 days, Minority Maternity Care, Social Determinants of Health. S. 657 - Drug Price Transparency (DPT) Act, S. 2543 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug and price transparency. H.R. 3- Lower Drug Costs Now Act of 2019, S. 102 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug costs and prescription rebates. Issues relating to drug and price transparency, including the Administrations rule on interoperability and Executive order on transparency.

H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Issues related to rural health access; health equity; Medicare Advantage; Medicaid Rebates; Medicaid Expansion; Rate Notice and Call Letter; Medicare Part D; NBPP, Part D Donut Hole; Privacy; Universal Coverage. H.R. 259, Medicaid Extenders Act of 2019, H.R. 4378, Continuing Appropriations Act of 2020: Issues related to Medicaid extension. HR 1398, S. 172 - Health Insurance Tax Relief Act of 2019, S. 80 - Jobs and Premium Protection Act; Issues related to repeal and delay the health insurer fee. Issues related to the Affordable Care Act reinsurance/stabilization. H.R. 861 - End Surprise Billing Act, HR 3630 - No Surprises Act, H.R. 3502 - Protecting People from Surprise Medical Bills Act; Issues relating to surprise billing, including benchmark payments, arbitration models, and out of network billing. S. 916 - MOMMAs Act, H.R. 2602, S. 1343 - MOMMIES Act, HR 4996 - Helping Medicaid Offer Maternity Services Act of 2019: Issues related to options for states to extend coverage for pregnant women eligible for Medicaid via the pregnancy pathway to 365 days, Minority Maternity Care, Social Determinants of Health. S. 657 - Drug Price Transparency (DPT) Act, S. 2543 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug and price transparency. H.R. 3- Lower Drug Costs Now Act of 2019, S. 102 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug costs and prescription rebates. Issues relating to drug and price transparency, including the Administrations rule on interoperability and Executive order on transparency.

H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Issues related to ACA reinsurance/stabilization; rural health access; health equity; Medicare Advantage; Medicaid Rebates; Medicaid Expansion; Rate Notice and Call Letter; Medicare Part D; NBPP, Part D Donut Hole; Prescription Rebates; Privacy; Universal Coverage. H.R. 3439 - Protecting Access To Information for Effective and Necessary Treatment Act, PATIENT Act: Regarding all provisions. H.R. 861 - End Surprise Billing Act, HR 3630 - No Surprises Act, H.R. 3502 - Protecting People from Surprise Medical Bills Act; Issues relating to surprise billing, including benchmark payments, arbitration models, and out of network billing. H.R. 1897, S. 916 - MOMMAs Act, H.R. 2602, S. 1343 - MOMMIES Act, H.R. 1551 - Quality Care for Moms and Babies Act, H.R. 2902 - Maternal Care Act: Issues related to options for states to extend coverage for pregnant women eligible for Medicaid via the pregnancy pathway to 365 days, Minority Maternity Care, Social Determinants of Health. S. 657 - Drug Price Transparency (DPT) Act, S. 2543 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug and price transparency. H.R. 3- Lower Drug Costs Now Act of 2019, S. 102 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug costs. Centers for Medicare and Medicaid Services 84 FR 39398 - Hospital Outpatient Prospective Payment System (OPPS); EO 13877 / 84 FR 30849 - Improving Price and Quality Transparency in American Healthcare To Put Patients First; Centers for Medicare and Medicaid Services Proposed Rule 84 FR 7610 - Interoperability and Patient Access; Office of National Coordinator for Health Information Technology Proposed Rule 84 FR 7424 - Interoperability, Information Blocking, and the ONC Health IT Certification Program; Issues relating to drug and price transparency.

H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Issues related to rural health access; health equity; Medicare Advantage; Medicaid Rebates; Medicaid Expansion; Rate Notice and Call Letter; Medicare Part D; NBPP, Part D Donut Hole; Privacy; Universal Coverage. H.R. 259, Medicaid Extenders Act of 2019, H.R. 4378, Continuing Appropriations Act of 2020: Issues related to Medicaid extension. HR 1398, S. 172 - Health Insurance Tax Relief Act of 2019, S. 80 - Jobs and Premium Protection Act; Issues related to repeal and delay the health insurer fee. Issues related to the Affordable Care Act reinsurance/stabilization. H.R. 861 - End Surprise Billing Act, HR 3630 - No Surprises Act, H.R. 3502 - Protecting People from Surprise Medical Bills Act; Issues relating to surprise billing, including benchmark payments, arbitration models, and out of network billing. S. 916 - MOMMAs Act, H.R. 2602, S. 1343 - MOMMIES Act, HR 4996 - Helping Medicaid Offer Maternity Services Act of 2019: Issues related to options for states to extend coverage for pregnant women eligible for Medicaid via the pregnancy pathway to 365 days, Minority Maternity Care, Social Determinants of Health. S. 657 - Drug Price Transparency (DPT) Act, S. 2543 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug and price transparency. H.R. 3- Lower Drug Costs Now Act of 2019, S. 102 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug costs and prescription rebates. Issues relating to drug and price transparency, including the Administrations rule on interoperability and Executive order on transparency.

H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Issues related to rural health access; health equity; Medicare Advantage; Medicaid Rebates; Medicaid Expansion; Rate Notice and Call Letter; Medicare Part D; NBPP, Part D Donut Hole; Privacy; Universal Coverage. H.R. 259, Medicaid Extenders Act of 2019, H.R. 4378, Continuing Appropriations Act of 2020: Issues related to Medicaid extension. HR 1398, S. 172 - Health Insurance Tax Relief Act of 2019, S. 80 - Jobs and Premium Protection Act; Issues related to repeal and delay the health insurer fee. Issues related to the Affordable Care Act reinsurance/stabilization. H.R. 861 - End Surprise Billing Act, HR 3630 - No Surprises Act, H.R. 3502 - Protecting People from Surprise Medical Bills Act; Issues relating to surprise billing, including benchmark payments, arbitration models, and out of network billing. S. 916 - MOMMAs Act, H.R. 2602, S. 1343 - MOMMIES Act, HR 4996 - Helping Medicaid Offer Maternity Services Act of 2019: Issues related to options for states to extend coverage for pregnant women eligible for Medicaid via the pregnancy pathway to 365 days, Minority Maternity Care, Social Determinants of Health. S. 657 - Drug Price Transparency (DPT) Act, S. 2543 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug and price transparency. H.R. 3- Lower Drug Costs Now Act of 2019, S. 102 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug costs and prescription rebates. Issues relating to drug and price transparency, including the Administrations rule on interoperability and Executive order on transparency.

H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Issues related to rural health access; health equity; Medicare Advantage; Medicaid Rebates; Medicaid Expansion; Rate Notice and Call Letter; Medicare Part D; NBPP, Part D Donut Hole; Privacy; Universal Coverage. H.R. 259, Medicaid Extenders Act of 2019, H.R. 4378, Continuing Appropriations Act of 2020: Issues related to Medicaid extension. HR 1398, S. 172 - Health Insurance Tax Relief Act of 2019, S. 80 - Jobs and Premium Protection Act; Issues related to repeal and delay the health insurer fee. Issues related to the Affordable Care Act reinsurance/stabilization. H.R. 861 - End Surprise Billing Act, HR 3630 - No Surprises Act, H.R. 3502 - Protecting People from Surprise Medical Bills Act; Issues relating to surprise billing, including benchmark payments, arbitration models, and out of network billing. S. 916 - MOMMAs Act, H.R. 2602, S. 1343 - MOMMIES Act, HR 4996 - Helping Medicaid Offer Maternity Services Act of 2019: Issues related to options for states to extend coverage for pregnant women eligible for Medicaid via the pregnancy pathway to 365 days, Minority Maternity Care, Social Determinants of Health. S. 657 - Drug Price Transparency (DPT) Act, S. 2543 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug and price transparency. H.R. 3- Lower Drug Costs Now Act of 2019, S. 102 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug costs and prescription rebates. Issues relating to drug and price transparency, including the Administrations rule on interoperability and Executive order on transparency.

H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Issues related to ACA reinsurance/stabilization; rural health access; health equity; Medicare Advantage; Medicaid Rebates; Medicaid Expansion; Rate Notice and Call Letter; Medicare Part D; NBPP, Part D Donut Hole; Prescription Rebates; Privacy; Universal Coverage. H.R. 3439 - Protecting Access To Information for Effective and Necessary Treatment Act, PATIENT Act: Regarding all provisions. H.R. 861 - End Surprise Billing Act, HR 3630 - No Surprises Act, H.R. 3502 - Protecting People from Surprise Medical Bills Act; Issues relating to surprise billing, including benchmark payments, arbitration models, and out of network billing. H.R. 1897, S. 916 - MOMMAs Act, H.R. 2602, S. 1343 - MOMMIES Act, H.R. 1551 - Quality Care for Moms and Babies Act, H.R. 2902 - Maternal Care Act: Issues related to options for states to extend coverage for pregnant women eligible for Medicaid via the pregnancy pathway to 365 days, Minority Maternity Care, Social Determinants of Health. S. 657 - Drug Price Transparency (DPT) Act, S. 2543 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug and price transparency. H.R. 3- Lower Drug Costs Now Act of 2019, S. 102 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug costs. Centers for Medicare and Medicaid Services 84 FR 39398 - Hospital Outpatient Prospective Payment System (OPPS); EO 13877 / 84 FR 30849 - Improving Price and Quality Transparency in American Healthcare To Put Patients First; Centers for Medicare and Medicaid Services Proposed Rule 84 FR 7610 - Interoperability and Patient Access; Office of National Coordinator for Health Information Technology Proposed Rule 84 FR 7424 - Interoperability, Information Blocking, and the ONC Health IT Certification Program; Issues relating to drug and price transparency.

H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Issues related to ACA reinsurance/stabilization; rural health access; health equity; Medicare Advantage; Medicaid Rebates; Medicaid Expansion; Rate Notice and Call Letter; Medicare Part D; NBPP, Part D Donut Hole; Prescription Rebates; Privacy; Universal Coverage. H.R. 3439 - Protecting Access To Information for Effective and Necessary Treatment Act, PATIENT Act: Regarding all provisions. H.R. 861 - End Surprise Billing Act, HR 3630 - No Surprises Act, H.R. 3502 - Protecting People from Surprise Medical Bills Act; Issues relating to surprise billing, including benchmark payments, arbitration models, and out of network billing. H.R. 1897, S. 916 - MOMMAs Act, H.R. 2602, S. 1343 - MOMMIES Act, H.R. 1551 - Quality Care for Moms and Babies Act, H.R. 2902 - Maternal Care Act: Issues related to options for states to extend coverage for pregnant women eligible for Medicaid via the pregnancy pathway to 365 days, Minority Maternity Care, Social Determinants of Health. S. 657 - Drug Price Transparency (DPT) Act, S. 2543 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug and price transparency. H.R. 3- Lower Drug Costs Now Act of 2019, S. 102 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug costs. Centers for Medicare and Medicaid Services 84 FR 39398 - Hospital Outpatient Prospective Payment System (OPPS); EO 13877 / 84 FR 30849 - Improving Price and Quality Transparency in American Healthcare To Put Patients First; Centers for Medicare and Medicaid Services Proposed Rule 84 FR 7610 - Interoperability and Patient Access; Office of National Coordinator for Health Information Technology Proposed Rule 84 FR 7424 - Interoperability, Information Blocking, and the ONC Health IT Certification Program; Issues relating to drug and price transparency.

H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Issues related to ACA reinsurance/stabilization; rural health access; health equity; Medicare Advantage; Medicaid Rebates; Medicaid Expansion; Rate Notice and Call Letter; Medicare Part D; NBPP, Part D Donut Hole; Prescription Rebates; Privacy; Universal Coverage. H.R. 3439 - Protecting Access To Information for Effective and Necessary Treatment Act, PATIENT Act: Regarding all provisions. H.R. 861 - End Surprise Billing Act, HR 3630 - No Surprises Act, H.R. 3502 - Protecting People from Surprise Medical Bills Act; Issues relating to surprise billing, including benchmark payments, arbitration models, and out of network billing. H.R. 1897, S. 916 - MOMMAs Act, H.R. 2602, S. 1343 - MOMMIES Act, H.R. 1551 - Quality Care for Moms and Babies Act, H.R. 2902 - Maternal Care Act: Issues related to options for states to extend coverage for pregnant women eligible for Medicaid via the pregnancy pathway to 365 days, Minority Maternity Care, Social Determinants of Health. S. 657 - Drug Price Transparency (DPT) Act, S. 2543 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug and price transparency. H.R. 3- Lower Drug Costs Now Act of 2019, S. 102 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug costs. Centers for Medicare and Medicaid Services 84 FR 39398 - Hospital Outpatient Prospective Payment System (OPPS); EO 13877 / 84 FR 30849 - Improving Price and Quality Transparency in American Healthcare To Put Patients First; Centers for Medicare and Medicaid Services Proposed Rule 84 FR 7610 - Interoperability and Patient Access; Office of National Coordinator for Health Information Technology Proposed Rule 84 FR 7424 - Interoperability, Information Blocking, and the ONC Health IT Certification Program; Issues relating to drug and price transparency.

H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Issues related to ACA reinsurance/stabilization; rural health access; health equity; Medicare Advantage; Medicaid Rebates; Medicaid Expansion; Rate Notice and Call Letter; Medicare Part D; NBPP, Part D Donut Hole; Prescription Rebates; Privacy; Universal Coverage. H.R. 3439 - Protecting Access To Information for Effective and Necessary Treatment Act, PATIENT Act: Regarding all provisions. H.R. 861 - End Surprise Billing Act, HR 3630 - No Surprises Act, H.R. 3502 - Protecting People from Surprise Medical Bills Act; Issues relating to surprise billing, including benchmark payments, arbitration models, and out of network billing. H.R. 1897, S. 916 - MOMMAs Act, H.R. 2602, S. 1343 - MOMMIES Act, H.R. 1551 - Quality Care for Moms and Babies Act, H.R. 2902 - Maternal Care Act: Issues related to options for states to extend coverage for pregnant women eligible for Medicaid via the pregnancy pathway to 365 days, Minority Maternity Care, Social Determinants of Health. S. 657 - Drug Price Transparency (DPT) Act, S. 2543 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug and price transparency. H.R. 3- Lower Drug Costs Now Act of 2019, S. 102 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug costs. Centers for Medicare and Medicaid Services 84 FR 39398 - Hospital Outpatient Prospective Payment System (OPPS); EO 13877 / 84 FR 30849 - Improving Price and Quality Transparency in American Healthcare To Put Patients First; Centers for Medicare and Medicaid Services Proposed Rule 84 FR 7610 - Interoperability and Patient Access; Office of National Coordinator for Health Information Technology Proposed Rule 84 FR 7424 - Interoperability, Information Blocking, and the ONC Health IT Certification Program; Issues relating to drug and price transparency.

H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Issues related to ACA reinsurance/stabilization; rural health access; health equity; Medicare Advantage; Medicaid Rebates; Medicaid Expansion; Rate Notice and Call Letter; Medicare Part D; NBPP, Part D Donut Hole; Prescription Rebates; Privacy; Universal Coverage. H.R. 3439 - Protecting Access To Information for Effective and Necessary Treatment Act, PATIENT Act: Regarding all provisions. H.R. 861 - End Surprise Billing Act, HR 3630 - No Surprises Act, H.R. 3502 - Protecting People from Surprise Medical Bills Act; Issues relating to surprise billing, including benchmark payments, arbitration models, and out of network billing. H.R. 1897, S. 916 - MOMMAs Act, H.R. 2602, S. 1343 - MOMMIES Act, H.R. 1551 - Quality Care for Moms and Babies Act, H.R. 2902 - Maternal Care Act: Issues related to options for states to extend coverage for pregnant women eligible for Medicaid via the pregnancy pathway to 365 days, Minority Maternity Care, Social Determinants of Health. S. 657 - Drug Price Transparency (DPT) Act, S. 2543 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug and price transparency. H.R. 3- Lower Drug Costs Now Act of 2019, S. 102 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug costs. Centers for Medicare and Medicaid Services 84 FR 39398 - Hospital Outpatient Prospective Payment System (OPPS); EO 13877 / 84 FR 30849 - Improving Price and Quality Transparency in American Healthcare To Put Patients First; Centers for Medicare and Medicaid Services Proposed Rule 84 FR 7610 - Interoperability and Patient Access; Office of National Coordinator for Health Information Technology Proposed Rule 84 FR 7424 - Interoperability, Information Blocking, and the ONC Health IT Certification Program; Issues relating to drug and price transparency.

H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Issues related to ACA reinsurance/stabilization; rural health access; health equity; Medicare Advantage; Medicaid Rebates; Medicaid Expansion; Rate Notice and Call Letter; Medicare Part D; NBPP, Part D Donut Hole; Prescription Rebates; Privacy; Universal Coverage. H.R. 3439 - Protecting Access To Information for Effective and Necessary Treatment Act, PATIENT Act: Regarding all provisions. H.R. 861 - End Surprise Billing Act, HR 3630 - No Surprises Act, H.R. 3502 - Protecting People from Surprise Medical Bills Act; Issues relating to surprise billing, including benchmark payments, arbitration models, and out of network billing. H.R. 1897, S. 916 - MOMMAs Act, H.R. 2602, S. 1343 - MOMMIES Act, H.R. 1551 - Quality Care for Moms and Babies Act, H.R. 2902 - Maternal Care Act: Issues related to options for states to extend coverage for pregnant women eligible for Medicaid via the pregnancy pathway to 365 days, Minority Maternity Care, Social Determinants of Health. S. 657 - Drug Price Transparency (DPT) Act, S. 2543 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug and price transparency. H.R. 3- Lower Drug Costs Now Act of 2019, S. 102 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug costs. Centers for Medicare and Medicaid Services 84 FR 39398 - Hospital Outpatient Prospective Payment System (OPPS); EO 13877 / 84 FR 30849 - Improving Price and Quality Transparency in American Healthcare To Put Patients First; Centers for Medicare and Medicaid Services Proposed Rule 84 FR 7610 - Interoperability and Patient Access; Office of National Coordinator for Health Information Technology Proposed Rule 84 FR 7424 - Interoperability, Information Blocking, and the ONC Health IT Certification Program; Issues relating to drug and price transparency.

H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Issues related to rural health access; health equity; Medicare Advantage; Medicaid Rebates; Medicaid Expansion; Rate Notice and Call Letter; Medicare Part D; NBPP, Part D Donut Hole; Privacy; Universal Coverage. H.R. 259, Medicaid Extenders Act of 2019, H.R. 4378, Continuing Appropriations Act of 2020: Issues related to Medicaid extension. HR 1398, S. 172 - Health Insurance Tax Relief Act of 2019, S. 80 - Jobs and Premium Protection Act; Issues related to repeal and delay the health insurer fee. Issues related to the Affordable Care Act reinsurance/stabilization. H.R. 861 - End Surprise Billing Act, HR 3630 - No Surprises Act, H.R. 3502 - Protecting People from Surprise Medical Bills Act; Issues relating to surprise billing, including benchmark payments, arbitration models, and out of network billing. S. 916 - MOMMAs Act, H.R. 2602, S. 1343 - MOMMIES Act, HR 4996 - Helping Medicaid Offer Maternity Services Act of 2019: Issues related to options for states to extend coverage for pregnant women eligible for Medicaid via the pregnancy pathway to 365 days, Minority Maternity Care, Social Determinants of Health. S. 657 - Drug Price Transparency (DPT) Act, S. 2543 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug and price transparency. H.R. 3- Lower Drug Costs Now Act of 2019, S. 102 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug costs and prescription rebates. Issues relating to drug and price transparency, including the Administrations rule on interoperability and Executive order on transparency.

H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Issues related to rural health access; health equity; Medicare Advantage; Medicaid Rebates; Medicaid Expansion; Rate Notice and Call Letter; Medicare Part D; NBPP, Part D Donut Hole; Privacy; Universal Coverage. H.R. 259, Medicaid Extenders Act of 2019, H.R. 4378, Continuing Appropriations Act of 2020: Issues related to Medicaid extension. HR 1398, S. 172 - Health Insurance Tax Relief Act of 2019, S. 80 - Jobs and Premium Protection Act; Issues related to repeal and delay the health insurer fee. Issues related to the Affordable Care Act reinsurance/stabilization. H.R. 861 - End Surprise Billing Act, HR 3630 - No Surprises Act, H.R. 3502 - Protecting People from Surprise Medical Bills Act; Issues relating to surprise billing, including benchmark payments, arbitration models, and out of network billing. S. 916 - MOMMAs Act, H.R. 2602, S. 1343 - MOMMIES Act, HR 4996 - Helping Medicaid Offer Maternity Services Act of 2019: Issues related to options for states to extend coverage for pregnant women eligible for Medicaid via the pregnancy pathway to 365 days, Minority Maternity Care, Social Determinants of Health. S. 657 - Drug Price Transparency (DPT) Act, S. 2543 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug and price transparency. H.R. 3- Lower Drug Costs Now Act of 2019, S. 102 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug costs and prescription rebates. Issues relating to drug and price transparency, including the Administrations rule on interoperability and Executive order on transparency.

H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Issues related to rural health access; health equity; Medicare Advantage; Medicaid Rebates; Medicaid Expansion; Rate Notice and Call Letter; Medicare Part D; NBPP, Part D Donut Hole; Privacy; Universal Coverage. H.R. 259, Medicaid Extenders Act of 2019, H.R. 4378, Continuing Appropriations Act of 2020: Issues related to Medicaid extension. HR 1398, S. 172 - Health Insurance Tax Relief Act of 2019, S. 80 - Jobs and Premium Protection Act; Issues related to repeal and delay the health insurer fee. Issues related to the Affordable Care Act reinsurance/stabilization. H.R. 861 - End Surprise Billing Act, HR 3630 - No Surprises Act, H.R. 3502 - Protecting People from Surprise Medical Bills Act; Issues relating to surprise billing, including benchmark payments, arbitration models, and out of network billing. S. 916 - MOMMAs Act, H.R. 2602, S. 1343 - MOMMIES Act, HR 4996 - Helping Medicaid Offer Maternity Services Act of 2019: Issues related to options for states to extend coverage for pregnant women eligible for Medicaid via the pregnancy pathway to 365 days, Minority Maternity Care, Social Determinants of Health. S. 657 - Drug Price Transparency (DPT) Act, S. 2543 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug and price transparency. H.R. 3- Lower Drug Costs Now Act of 2019, S. 102 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug costs and prescription rebates. Issues relating to drug and price transparency, including the Administrations rule on interoperability and Executive order on transparency.

H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Issues related to ACA reinsurance/stabilization; rural health access; health equity; Medicare Advantage; Medicaid Rebates; Medicaid Expansion; Rate Notice and Call Letter; Medicare Part D; NBPP, Part D Donut Hole; Prescription Rebates; Privacy; Universal Coverage. H.R. 3439 - Protecting Access To Information for Effective and Necessary Treatment Act, PATIENT Act: Regarding all provisions. H.R. 861 - End Surprise Billing Act, HR 3630 - No Surprises Act, H.R. 3502 - Protecting People from Surprise Medical Bills Act; Issues relating to surprise billing, including benchmark payments, arbitration models, and out of network billing. H.R. 1897, S. 916 - MOMMAs Act, H.R. 2602, S. 1343 - MOMMIES Act, H.R. 1551 - Quality Care for Moms and Babies Act, H.R. 2902 - Maternal Care Act: Issues related to options for states to extend coverage for pregnant women eligible for Medicaid via the pregnancy pathway to 365 days, Minority Maternity Care, Social Determinants of Health. S. 657 - Drug Price Transparency (DPT) Act, S. 2543 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug and price transparency. H.R. 3- Lower Drug Costs Now Act of 2019, S. 102 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug costs. Centers for Medicare and Medicaid Services 84 FR 39398 - Hospital Outpatient Prospective Payment System (OPPS); EO 13877 / 84 FR 30849 - Improving Price and Quality Transparency in American Healthcare To Put Patients First; Centers for Medicare and Medicaid Services Proposed Rule 84 FR 7610 - Interoperability and Patient Access; Office of National Coordinator for Health Information Technology Proposed Rule 84 FR 7424 - Interoperability, Information Blocking, and the ONC Health IT Certification Program; Issues relating to drug and price transparency.

H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Issues related to ACA reinsurance/stabilization; rural health access; health equity; Medicare Advantage; Medicaid Rebates; Medicaid Expansion; Rate Notice and Call Letter; Medicare Part D; NBPP, Part D Donut Hole; Prescription Rebates; Privacy; Universal Coverage. H.R. 3439 - Protecting Access To Information for Effective and Necessary Treatment Act, PATIENT Act: Regarding all provisions. H.R. 861 - End Surprise Billing Act, HR 3630 - No Surprises Act, H.R. 3502 - Protecting People from Surprise Medical Bills Act; Issues relating to surprise billing, including benchmark payments, arbitration models, and out of network billing. H.R. 1897, S. 916 - MOMMAs Act, H.R. 2602, S. 1343 - MOMMIES Act, H.R. 1551 - Quality Care for Moms and Babies Act, H.R. 2902 - Maternal Care Act: Issues related to options for states to extend coverage for pregnant women eligible for Medicaid via the pregnancy pathway to 365 days, Minority Maternity Care, Social Determinants of Health. S. 657 - Drug Price Transparency (DPT) Act, S. 2543 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug and price transparency. H.R. 3- Lower Drug Costs Now Act of 2019, S. 102 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug costs. Centers for Medicare and Medicaid Services 84 FR 39398 - Hospital Outpatient Prospective Payment System (OPPS); EO 13877 / 84 FR 30849 - Improving Price and Quality Transparency in American Healthcare To Put Patients First; Centers for Medicare and Medicaid Services Proposed Rule 84 FR 7610 - Interoperability and Patient Access; Office of National Coordinator for Health Information Technology Proposed Rule 84 FR 7424 - Interoperability, Information Blocking, and the ONC Health IT Certification Program; Issues relating to drug and price transparency.

H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Issues related to ACA reinsurance/stabilization; rural health access; health equity; Medicare Advantage; Medicaid Rebates; Medicaid Expansion; Rate Notice and Call Letter; Medicare Part D; NBPP, Part D Donut Hole; Prescription Rebates; Privacy; Universal Coverage. H.R. 3439 - Protecting Access To Information for Effective and Necessary Treatment Act, PATIENT Act: Regarding all provisions. H.R. 861 - End Surprise Billing Act, HR 3630 - No Surprises Act, H.R. 3502 - Protecting People from Surprise Medical Bills Act; Issues relating to surprise billing, including benchmark payments, arbitration models, and out of network billing. H.R. 1897, S. 916 - MOMMAs Act, H.R. 2602, S. 1343 - MOMMIES Act, H.R. 1551 - Quality Care for Moms and Babies Act, H.R. 2902 - Maternal Care Act: Issues related to options for states to extend coverage for pregnant women eligible for Medicaid via the pregnancy pathway to 365 days, Minority Maternity Care, Social Determinants of Health. S. 657 - Drug Price Transparency (DPT) Act, S. 2543 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug and price transparency. H.R. 3- Lower Drug Costs Now Act of 2019, S. 102 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug costs. Centers for Medicare and Medicaid Services 84 FR 39398 - Hospital Outpatient Prospective Payment System (OPPS); EO 13877 / 84 FR 30849 - Improving Price and Quality Transparency in American Healthcare To Put Patients First; Centers for Medicare and Medicaid Services Proposed Rule 84 FR 7610 - Interoperability and Patient Access; Office of National Coordinator for Health Information Technology Proposed Rule 84 FR 7424 - Interoperability, Information Blocking, and the ONC Health IT Certification Program; Issues relating to drug and price transparency.

H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Issues related to ACA reinsurance/stabilization; rural health access; health equity; Medicare Advantage; Medicaid Rebates; Medicaid Expansion; Rate Notice and Call Letter; Medicare Part D; NBPP, Part D Donut Hole; Prescription Rebates; Privacy; Universal Coverage. H.R. 3439 - Protecting Access To Information for Effective and Necessary Treatment Act, PATIENT Act: Regarding all provisions. H.R. 861 - End Surprise Billing Act, HR 3630 - No Surprises Act, H.R. 3502 - Protecting People from Surprise Medical Bills Act; Issues relating to surprise billing, including benchmark payments, arbitration models, and out of network billing. H.R. 1897, S. 916 - MOMMAs Act, H.R. 2602, S. 1343 - MOMMIES Act, H.R. 1551 - Quality Care for Moms and Babies Act, H.R. 2902 - Maternal Care Act: Issues related to options for states to extend coverage for pregnant women eligible for Medicaid via the pregnancy pathway to 365 days, Minority Maternity Care, Social Determinants of Health. S. 657 - Drug Price Transparency (DPT) Act, S. 2543 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug and price transparency. H.R. 3- Lower Drug Costs Now Act of 2019, S. 102 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug costs. Centers for Medicare and Medicaid Services 84 FR 39398 - Hospital Outpatient Prospective Payment System (OPPS); EO 13877 / 84 FR 30849 - Improving Price and Quality Transparency in American Healthcare To Put Patients First; Centers for Medicare and Medicaid Services Proposed Rule 84 FR 7610 - Interoperability and Patient Access; Office of National Coordinator for Health Information Technology Proposed Rule 84 FR 7424 - Interoperability, Information Blocking, and the ONC Health IT Certification Program; Issues relating to drug and price transparency.

H.R. 1781 - Payment Commission Data Act of 2019: Issues regarding providing the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to drug pricing and rebate data. H.R. 938 - Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019: Issues regarding discouraging parking of 180-day exclusivity by a first generic applicant that is blocking the approval of other generics. H.R. 1520 - Purple Book Continuity Act of 2019: Issues regarding codifying publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book; Publication and regular updating of the Purple Book electronically on the FDAs website. H.R. 1503 - Orange Book Transparency Act of 2019: Issues regarding ensuring that the Orange Book is accurate and up-to-date, by requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019: Issues regarding brand-name and generic drug manufacturers entering into agreements in which the brand-name drug manufacturer pays the generic manufacturer to keep a generic equivalent off the market. H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 1385 - State Allowance for a Variety of Exchanges (SAVE) Act: Issues regarding federal funds to establish state-based Marketplaces. H.R. 1386 - Expand Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act: Issues regarding funding for Federally-Facilitated Marketplace navigator program; requirements for navigator entities in each state; Health and Human Services ensuring that navigator grants are awarded to entities with demonstrated capacity to carry out the duties specified in the Affordable Care Act. H.R. 987 - Marketing and Outreach Restoration to Empower (MORE) Health Education Act of 2019: Issues related to restoring outreach and enrollment funding to assist consumers in signing up for health care. H.R. 1010 - Issues regarding Short-Term, Limited Duration Insurance. H.R. 986 - Protecting Americans with Preexisting Conditions Act of 2019: Issues regarding rescinding Section 1332 guidance of the ACA promulgated in October 2018. H.R. 1425 - State Health Care Premium Reduction Act: Issues regarding state reinsurance program and providing financial assistance to reduce out-of-pocket costs. H.R. 820 - Public Health Service Act: Issues regarding National Institutes of Health support to collect the medical specimens and information of children with selected cancers that have the least effective treatments. H.R. 2069 - The SPIKE Act, H.R. 2113 - STAR Act, H.R. 2115 - Public Disclosure of Drug Discounts Act, H.R. 2296 - FAIR Drug Pricing Act, H.R. 2376 - Prescription Pricing for the People Act, H.R, 2757 - Creating Lower Cost Alternatives for Your Prescription Drugs Act, S. 657 - Drug Price Transparency (DPT) Act: Issues relating to drug and price transparency. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Regarding all provisions. S. 80, S. 172 - Issues regarding repeal and delay of the health insurer fee. Issues pertaining to surprise billing, including benchmark payments and arbitration models.

H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Issues related to rural health access; health equity; Medicare Advantage; Medicaid Rebates; Medicaid Expansion; Rate Notice and Call Letter; Medicare Part D; NBPP, Part D Donut Hole; Privacy; Universal Coverage. H.R. 259, Medicaid Extenders Act of 2019, H.R. 4378, Continuing Appropriations Act of 2020: Issues related to Medicaid extension. HR 1398, S. 172 - Health Insurance Tax Relief Act of 2019, S. 80 - Jobs and Premium Protection Act; Issues related to repeal and delay the health insurer fee. Issues related to the Affordable Care Act reinsurance/stabilization. H.R. 861 - End Surprise Billing Act, HR 3630 - No Surprises Act, H.R. 3502 - Protecting People from Surprise Medical Bills Act; Issues relating to surprise billing, including benchmark payments, arbitration models, and out of network billing. S. 916 - MOMMAs Act, H.R. 2602, S. 1343 - MOMMIES Act, HR 4996 - Helping Medicaid Offer Maternity Services Act of 2019: Issues related to options for states to extend coverage for pregnant women eligible for Medicaid via the pregnancy pathway to 365 days, Minority Maternity Care, Social Determinants of Health. S. 657 - Drug Price Transparency (DPT) Act, S. 2543 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug and price transparency. H.R. 3- Lower Drug Costs Now Act of 2019, S. 102 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug costs and prescription rebates. Issues relating to drug and price transparency, including the Administrations rule on interoperability and Executive order on transparency.

H.R. 1781 - Payment Commission Data Act of 2019: Issues regarding providing the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to drug pricing and rebate data. H.R. 938 - Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019: Issues regarding discouraging parking of 180-day exclusivity by a first generic applicant that is blocking the approval of other generics. H.R. 1520 - Purple Book Continuity Act of 2019: Issues regarding codifying publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book; Publication and regular updating of the Purple Book electronically on the FDAs website. H.R. 1503 - Orange Book Transparency Act of 2019: Issues regarding ensuring that the Orange Book is accurate and up-to-date, by requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019: Issues regarding brand-name and generic drug manufacturers entering into agreements in which the brand-name drug manufacturer pays the generic manufacturer to keep a generic equivalent off the market. H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 1385 - State Allowance for a Variety of Exchanges (SAVE) Act: Issues regarding federal funds to establish state-based Marketplaces. H.R. 1386 - Expand Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act: Issues regarding funding for Federally-Facilitated Marketplace navigator program; requirements for navigator entities in each state; Health and Human Services ensuring that navigator grants are awarded to entities with demonstrated capacity to carry out the duties specified in the Affordable Care Act. H.R. 987 - Marketing and Outreach Restoration to Empower (MORE) Health Education Act of 2019: Issues related to restoring outreach and enrollment funding to assist consumers in signing up for health care. H.R. 1010 - Issues regarding Short-Term, Limited Duration Insurance. H.R. 986 - Protecting Americans with Preexisting Conditions Act of 2019: Issues regarding rescinding Section 1332 guidance of the ACA promulgated in October 2018. H.R. 1425 - State Health Care Premium Reduction Act: Issues regarding state reinsurance program and providing financial assistance to reduce out-of-pocket costs. H.R. 820 - Public Health Service Act: Issues regarding National Institutes of Health support to collect the medical specimens and information of children with selected cancers that have the least effective treatments. H.R. 2069 - The SPIKE Act, H.R. 2113 - STAR Act, H.R. 2115 - Public Disclosure of Drug Discounts Act, H.R. 2296 - FAIR Drug Pricing Act, H.R. 2376 - Prescription Pricing for the People Act, H.R, 2757 - Creating Lower Cost Alternatives for Your Prescription Drugs Act, S. 657 - Drug Price Transparency (DPT) Act: Issues relating to drug and price transparency. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Regarding all provisions. S. 80, S. 172 - Issues regarding repeal and delay of the health insurer fee. Issues pertaining to surprise billing, including benchmark payments and arbitration models.

H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Issues related to ACA reinsurance/stabilization; rural health access; health equity; Medicare Advantage; Medicaid Rebates; Medicaid Expansion; Rate Notice and Call Letter; Medicare Part D; NBPP, Part D Donut Hole; Prescription Rebates; Privacy; Universal Coverage. H.R. 3439 - Protecting Access To Information for Effective and Necessary Treatment Act, PATIENT Act: Regarding all provisions. H.R. 861 - End Surprise Billing Act, HR 3630 - No Surprises Act, H.R. 3502 - Protecting People from Surprise Medical Bills Act; Issues relating to surprise billing, including benchmark payments, arbitration models, and out of network billing. H.R. 1897, S. 916 - MOMMAs Act, H.R. 2602, S. 1343 - MOMMIES Act, H.R. 1551 - Quality Care for Moms and Babies Act, H.R. 2902 - Maternal Care Act: Issues related to options for states to extend coverage for pregnant women eligible for Medicaid via the pregnancy pathway to 365 days, Minority Maternity Care, Social Determinants of Health. S. 657 - Drug Price Transparency (DPT) Act, S. 2543 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug and price transparency. H.R. 3- Lower Drug Costs Now Act of 2019, S. 102 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug costs. Centers for Medicare and Medicaid Services 84 FR 39398 - Hospital Outpatient Prospective Payment System (OPPS); EO 13877 / 84 FR 30849 - Improving Price and Quality Transparency in American Healthcare To Put Patients First; Centers for Medicare and Medicaid Services Proposed Rule 84 FR 7610 - Interoperability and Patient Access; Office of National Coordinator for Health Information Technology Proposed Rule 84 FR 7424 - Interoperability, Information Blocking, and the ONC Health IT Certification Program; Issues relating to drug and price transparency.

H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Issues related to rural health access; health equity; Medicare Advantage; Medicaid Rebates; Medicaid Expansion; Rate Notice and Call Letter; Medicare Part D; NBPP, Part D Donut Hole; Privacy; Universal Coverage. H.R. 259, Medicaid Extenders Act of 2019, H.R. 4378, Continuing Appropriations Act of 2020: Issues related to Medicaid extension. HR 1398, S. 172 - Health Insurance Tax Relief Act of 2019, S. 80 - Jobs and Premium Protection Act; Issues related to repeal and delay the health insurer fee. Issues related to the Affordable Care Act reinsurance/stabilization. H.R. 861 - End Surprise Billing Act, HR 3630 - No Surprises Act, H.R. 3502 - Protecting People from Surprise Medical Bills Act; Issues relating to surprise billing, including benchmark payments, arbitration models, and out of network billing. S. 916 - MOMMAs Act, H.R. 2602, S. 1343 - MOMMIES Act, HR 4996 - Helping Medicaid Offer Maternity Services Act of 2019: Issues related to options for states to extend coverage for pregnant women eligible for Medicaid via the pregnancy pathway to 365 days, Minority Maternity Care, Social Determinants of Health. S. 657 - Drug Price Transparency (DPT) Act, S. 2543 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug and price transparency. H.R. 3- Lower Drug Costs Now Act of 2019, S. 102 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug costs and prescription rebates. Issues relating to drug and price transparency, including the Administrations rule on interoperability and Executive order on transparency.

H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Issues related to rural health access; health equity; Medicare Advantage; Medicaid Rebates; Medicaid Expansion; Rate Notice and Call Letter; Medicare Part D; NBPP, Part D Donut Hole; Privacy; Universal Coverage. H.R. 259, Medicaid Extenders Act of 2019, H.R. 4378, Continuing Appropriations Act of 2020: Issues related to Medicaid extension. HR 1398, S. 172 - Health Insurance Tax Relief Act of 2019, S. 80 - Jobs and Premium Protection Act; Issues related to repeal and delay the health insurer fee. Issues related to the Affordable Care Act reinsurance/stabilization. H.R. 861 - End Surprise Billing Act, HR 3630 - No Surprises Act, H.R. 3502 - Protecting People from Surprise Medical Bills Act; Issues relating to surprise billing, including benchmark payments, arbitration models, and out of network billing. S. 916 - MOMMAs Act, H.R. 2602, S. 1343 - MOMMIES Act, HR 4996 - Helping Medicaid Offer Maternity Services Act of 2019: Issues related to options for states to extend coverage for pregnant women eligible for Medicaid via the pregnancy pathway to 365 days, Minority Maternity Care, Social Determinants of Health. S. 657 - Drug Price Transparency (DPT) Act, S. 2543 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug and price transparency. H.R. 3- Lower Drug Costs Now Act of 2019, S. 102 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug costs and prescription rebates. Issues relating to drug and price transparency, including the Administrations rule on interoperability and Executive order on transparency.

H.R. 1781 - Payment Commission Data Act of 2019: Issues regarding providing the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to drug pricing and rebate data. H.R. 938 - Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019: Issues regarding discouraging parking of 180-day exclusivity by a first generic applicant that is blocking the approval of other generics. H.R. 1520 - Purple Book Continuity Act of 2019: Issues regarding codifying publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book; Publication and regular updating of the Purple Book electronically on the FDAs website. H.R. 1503 - Orange Book Transparency Act of 2019: Issues regarding ensuring that the Orange Book is accurate and up-to-date, by requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019: Issues regarding brand-name and generic drug manufacturers entering into agreements in which the brand-name drug manufacturer pays the generic manufacturer to keep a generic equivalent off the market. H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 1385 - State Allowance for a Variety of Exchanges (SAVE) Act: Issues regarding federal funds to establish state-based Marketplaces. H.R. 1386 - Expand Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act: Issues regarding funding for Federally-Facilitated Marketplace navigator program; requirements for navigator entities in each state; Health and Human Services ensuring that navigator grants are awarded to entities with demonstrated capacity to carry out the duties specified in the Affordable Care Act. H.R. 987 - Marketing and Outreach Restoration to Empower (MORE) Health Education Act of 2019: Issues related to restoring outreach and enrollment funding to assist consumers in signing up for health care. H.R. 1010 - Issues regarding Short-Term, Limited Duration Insurance. H.R. 986 - Protecting Americans with Preexisting Conditions Act of 2019: Issues regarding rescinding Section 1332 guidance of the ACA promulgated in October 2018. H.R. 1425 - State Health Care Premium Reduction Act: Issues regarding state reinsurance program and providing financial assistance to reduce out-of-pocket costs. H.R. 820 - Public Health Service Act: Issues regarding National Institutes of Health support to collect the medical specimens and information of children with selected cancers that have the least effective treatments. H.R. 2069 - The SPIKE Act, H.R. 2113 - STAR Act, H.R. 2115 - Public Disclosure of Drug Discounts Act, H.R. 2296 - FAIR Drug Pricing Act, H.R. 2376 - Prescription Pricing for the People Act, H.R, 2757 - Creating Lower Cost Alternatives for Your Prescription Drugs Act, S. 657 - Drug Price Transparency (DPT) Act: Issues relating to drug and price transparency. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Regarding all provisions. S. 80, S. 172 - Issues regarding repeal and delay of the health insurer fee. Issues pertaining to surprise billing, including benchmark payments and arbitration models.

H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Issues related to ACA reinsurance/stabilization; rural health access; health equity; Medicare Advantage; Medicaid Rebates; Medicaid Expansion; Rate Notice and Call Letter; Medicare Part D; NBPP, Part D Donut Hole; Prescription Rebates; Privacy; Universal Coverage. H.R. 3439 - Protecting Access To Information for Effective and Necessary Treatment Act, PATIENT Act: Regarding all provisions. H.R. 861 - End Surprise Billing Act, HR 3630 - No Surprises Act, H.R. 3502 - Protecting People from Surprise Medical Bills Act; Issues relating to surprise billing, including benchmark payments, arbitration models, and out of network billing. H.R. 1897, S. 916 - MOMMAs Act, H.R. 2602, S. 1343 - MOMMIES Act, H.R. 1551 - Quality Care for Moms and Babies Act, H.R. 2902 - Maternal Care Act: Issues related to options for states to extend coverage for pregnant women eligible for Medicaid via the pregnancy pathway to 365 days, Minority Maternity Care, Social Determinants of Health. S. 657 - Drug Price Transparency (DPT) Act, S. 2543 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug and price transparency. H.R. 3- Lower Drug Costs Now Act of 2019, S. 102 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug costs. Centers for Medicare and Medicaid Services 84 FR 39398 - Hospital Outpatient Prospective Payment System (OPPS); EO 13877 / 84 FR 30849 - Improving Price and Quality Transparency in American Healthcare To Put Patients First; Centers for Medicare and Medicaid Services Proposed Rule 84 FR 7610 - Interoperability and Patient Access; Office of National Coordinator for Health Information Technology Proposed Rule 84 FR 7424 - Interoperability, Information Blocking, and the ONC Health IT Certification Program; Issues relating to drug and price transparency.

H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Issues related to ACA reinsurance/stabilization; rural health access; health equity; Medicare Advantage; Medicaid Rebates; Medicaid Expansion; Rate Notice and Call Letter; Medicare Part D; NBPP, Part D Donut Hole; Prescription Rebates; Privacy; Universal Coverage. H.R. 3439 - Protecting Access To Information for Effective and Necessary Treatment Act, PATIENT Act: Regarding all provisions. H.R. 861 - End Surprise Billing Act, HR 3630 - No Surprises Act, H.R. 3502 - Protecting People from Surprise Medical Bills Act; Issues relating to surprise billing, including benchmark payments, arbitration models, and out of network billing. H.R. 1897, S. 916 - MOMMAs Act, H.R. 2602, S. 1343 - MOMMIES Act, H.R. 1551 - Quality Care for Moms and Babies Act, H.R. 2902 - Maternal Care Act: Issues related to options for states to extend coverage for pregnant women eligible for Medicaid via the pregnancy pathway to 365 days, Minority Maternity Care, Social Determinants of Health. S. 657 - Drug Price Transparency (DPT) Act, S. 2543 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug and price transparency. H.R. 3- Lower Drug Costs Now Act of 2019, S. 102 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug costs. Centers for Medicare and Medicaid Services 84 FR 39398 - Hospital Outpatient Prospective Payment System (OPPS); EO 13877 / 84 FR 30849 - Improving Price and Quality Transparency in American Healthcare To Put Patients First; Centers for Medicare and Medicaid Services Proposed Rule 84 FR 7610 - Interoperability and Patient Access; Office of National Coordinator for Health Information Technology Proposed Rule 84 FR 7424 - Interoperability, Information Blocking, and the ONC Health IT Certification Program; Issues relating to drug and price transparency.

H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Issues related to ACA reinsurance/stabilization; rural health access; health equity; Medicare Advantage; Medicaid Rebates; Medicaid Expansion; Rate Notice and Call Letter; Medicare Part D; NBPP, Part D Donut Hole; Prescription Rebates; Privacy; Universal Coverage. H.R. 3439 - Protecting Access To Information for Effective and Necessary Treatment Act, PATIENT Act: Regarding all provisions. H.R. 861 - End Surprise Billing Act, HR 3630 - No Surprises Act, H.R. 3502 - Protecting People from Surprise Medical Bills Act; Issues relating to surprise billing, including benchmark payments, arbitration models, and out of network billing. H.R. 1897, S. 916 - MOMMAs Act, H.R. 2602, S. 1343 - MOMMIES Act, H.R. 1551 - Quality Care for Moms and Babies Act, H.R. 2902 - Maternal Care Act: Issues related to options for states to extend coverage for pregnant women eligible for Medicaid via the pregnancy pathway to 365 days, Minority Maternity Care, Social Determinants of Health. S. 657 - Drug Price Transparency (DPT) Act, S. 2543 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug and price transparency. H.R. 3- Lower Drug Costs Now Act of 2019, S. 102 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug costs. Centers for Medicare and Medicaid Services 84 FR 39398 - Hospital Outpatient Prospective Payment System (OPPS); EO 13877 / 84 FR 30849 - Improving Price and Quality Transparency in American Healthcare To Put Patients First; Centers for Medicare and Medicaid Services Proposed Rule 84 FR 7610 - Interoperability and Patient Access; Office of National Coordinator for Health Information Technology Proposed Rule 84 FR 7424 - Interoperability, Information Blocking, and the ONC Health IT Certification Program; Issues relating to drug and price transparency.

H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Issues related to rural health access; health equity; Medicare Advantage; Medicaid Rebates; Medicaid Expansion; Rate Notice and Call Letter; Medicare Part D; NBPP, Part D Donut Hole; Privacy; Universal Coverage. H.R. 259, Medicaid Extenders Act of 2019, H.R. 4378, Continuing Appropriations Act of 2020: Issues related to Medicaid extension. HR 1398, S. 172 - Health Insurance Tax Relief Act of 2019, S. 80 - Jobs and Premium Protection Act; Issues related to repeal and delay the health insurer fee. Issues related to the Affordable Care Act reinsurance/stabilization. H.R. 861 - End Surprise Billing Act, HR 3630 - No Surprises Act, H.R. 3502 - Protecting People from Surprise Medical Bills Act; Issues relating to surprise billing, including benchmark payments, arbitration models, and out of network billing. S. 916 - MOMMAs Act, H.R. 2602, S. 1343 - MOMMIES Act, HR 4996 - Helping Medicaid Offer Maternity Services Act of 2019: Issues related to options for states to extend coverage for pregnant women eligible for Medicaid via the pregnancy pathway to 365 days, Minority Maternity Care, Social Determinants of Health. S. 657 - Drug Price Transparency (DPT) Act, S. 2543 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug and price transparency. H.R. 3- Lower Drug Costs Now Act of 2019, S. 102 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug costs and prescription rebates. Issues relating to drug and price transparency, including the Administrations rule on interoperability and Executive order on transparency.

H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Issues related to ACA reinsurance/stabilization; rural health access; health equity; Medicare Advantage; Medicaid Rebates; Medicaid Expansion; Rate Notice and Call Letter; Medicare Part D; NBPP, Part D Donut Hole; Prescription Rebates; Privacy; Universal Coverage. H.R. 3439 - Protecting Access To Information for Effective and Necessary Treatment Act, PATIENT Act: Regarding all provisions. H.R. 861 - End Surprise Billing Act, HR 3630 - No Surprises Act, H.R. 3502 - Protecting People from Surprise Medical Bills Act; Issues relating to surprise billing, including benchmark payments, arbitration models, and out of network billing. H.R. 1897, S. 916 - MOMMAs Act, H.R. 2602, S. 1343 - MOMMIES Act, H.R. 1551 - Quality Care for Moms and Babies Act, H.R. 2902 - Maternal Care Act: Issues related to options for states to extend coverage for pregnant women eligible for Medicaid via the pregnancy pathway to 365 days, Minority Maternity Care, Social Determinants of Health. S. 657 - Drug Price Transparency (DPT) Act, S. 2543 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug and price transparency. H.R. 3- Lower Drug Costs Now Act of 2019, S. 102 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug costs. Centers for Medicare and Medicaid Services 84 FR 39398 - Hospital Outpatient Prospective Payment System (OPPS); EO 13877 / 84 FR 30849 - Improving Price and Quality Transparency in American Healthcare To Put Patients First; Centers for Medicare and Medicaid Services Proposed Rule 84 FR 7610 - Interoperability and Patient Access; Office of National Coordinator for Health Information Technology Proposed Rule 84 FR 7424 - Interoperability, Information Blocking, and the ONC Health IT Certification Program; Issues relating to drug and price transparency.

H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Issues related to rural health access; health equity; Medicare Advantage; Medicaid Rebates; Medicaid Expansion; Rate Notice and Call Letter; Medicare Part D; NBPP, Part D Donut Hole; Privacy; Universal Coverage. H.R. 259, Medicaid Extenders Act of 2019, H.R. 4378, Continuing Appropriations Act of 2020: Issues related to Medicaid extension. HR 1398, S. 172 - Health Insurance Tax Relief Act of 2019, S. 80 - Jobs and Premium Protection Act; Issues related to repeal and delay the health insurer fee. Issues related to the Affordable Care Act reinsurance/stabilization. H.R. 861 - End Surprise Billing Act, HR 3630 - No Surprises Act, H.R. 3502 - Protecting People from Surprise Medical Bills Act; Issues relating to surprise billing, including benchmark payments, arbitration models, and out of network billing. S. 916 - MOMMAs Act, H.R. 2602, S. 1343 - MOMMIES Act, HR 4996 - Helping Medicaid Offer Maternity Services Act of 2019: Issues related to options for states to extend coverage for pregnant women eligible for Medicaid via the pregnancy pathway to 365 days, Minority Maternity Care, Social Determinants of Health. S. 657 - Drug Price Transparency (DPT) Act, S. 2543 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug and price transparency. H.R. 3- Lower Drug Costs Now Act of 2019, S. 102 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug costs and prescription rebates. Issues relating to drug and price transparency, including the Administrations rule on interoperability and Executive order on transparency.

H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Issues related to rural health access; health equity; Medicare Advantage; Medicaid Rebates; Medicaid Expansion; Rate Notice and Call Letter; Medicare Part D; NBPP, Part D Donut Hole; Privacy; Universal Coverage. H.R. 259, Medicaid Extenders Act of 2019, H.R. 4378, Continuing Appropriations Act of 2020: Issues related to Medicaid extension. HR 1398, S. 172 - Health Insurance Tax Relief Act of 2019, S. 80 - Jobs and Premium Protection Act; Issues related to repeal and delay the health insurer fee. Issues related to the Affordable Care Act reinsurance/stabilization. H.R. 861 - End Surprise Billing Act, HR 3630 - No Surprises Act, H.R. 3502 - Protecting People from Surprise Medical Bills Act; Issues relating to surprise billing, including benchmark payments, arbitration models, and out of network billing. S. 916 - MOMMAs Act, H.R. 2602, S. 1343 - MOMMIES Act, HR 4996 - Helping Medicaid Offer Maternity Services Act of 2019: Issues related to options for states to extend coverage for pregnant women eligible for Medicaid via the pregnancy pathway to 365 days, Minority Maternity Care, Social Determinants of Health. S. 657 - Drug Price Transparency (DPT) Act, S. 2543 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug and price transparency. H.R. 3- Lower Drug Costs Now Act of 2019, S. 102 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug costs and prescription rebates. Issues relating to drug and price transparency, including the Administrations rule on interoperability and Executive order on transparency.

H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Issues related to ACA reinsurance/stabilization; rural health access; health equity; Medicare Advantage; Medicaid Rebates; Medicaid Expansion; Rate Notice and Call Letter; Medicare Part D; NBPP, Part D Donut Hole; Prescription Rebates; Privacy; Universal Coverage. H.R. 3439 - Protecting Access To Information for Effective and Necessary Treatment Act, PATIENT Act: Regarding all provisions. H.R. 861 - End Surprise Billing Act, HR 3630 - No Surprises Act, H.R. 3502 - Protecting People from Surprise Medical Bills Act; Issues relating to surprise billing, including benchmark payments, arbitration models, and out of network billing. H.R. 1897, S. 916 - MOMMAs Act, H.R. 2602, S. 1343 - MOMMIES Act, H.R. 1551 - Quality Care for Moms and Babies Act, H.R. 2902 - Maternal Care Act: Issues related to options for states to extend coverage for pregnant women eligible for Medicaid via the pregnancy pathway to 365 days, Minority Maternity Care, Social Determinants of Health. S. 657 - Drug Price Transparency (DPT) Act, S. 2543 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug and price transparency. H.R. 3- Lower Drug Costs Now Act of 2019, S. 102 - Prescription Drug Pricing Reduction Act of 2019: Issues relating to drug costs. Centers for Medicare and Medicaid Services 84 FR 39398 - Hospital Outpatient Prospective Payment System (OPPS); EO 13877 / 84 FR 30849 - Improving Price and Quality Transparency in American Healthcare To Put Patients First; Centers for Medicare and Medicaid Services Proposed Rule 84 FR 7610 - Interoperability and Patient Access; Office of National Coordinator for Health Information Technology Proposed Rule 84 FR 7424 - Interoperability, Information Blocking, and the ONC Health IT Certification Program; Issues relating to drug and price transparency.